

CONSENSUS-BASED EXPERT RECOMMENDATIONS FOR DIAGNOSIS AND CLINICAL MANAGEMENT OF VANISHING WHITE MATTER

Neurology. 2025;105(11):e214320.
doi:10.1212/WNL.00000000000214320

EUROPEAN REFERENCE NETWORKS
FOR RARE, LOW PREVALENCE AND COMPLEX DISEASES

Share. Care. Cure.



Endorsed by ERN-RND: 24.June.2026

Published by ERN-RND: 10 July 2026

Disclaimer:

“The European Commission support for the production of this publication does not constitute endorsement of the contents which reflects the views only of the authors, and the Commission cannot be held responsible for any use which may be made of the information contained therein.”

More information on the European Union is available on the Internet (<http://europa.eu>).

Luxembourg: Publications Office of the European Union, 2019

© European Union, 2019

Reproduction is authorised provided the source is acknowledged.

THE EUROPEAN REFERENCE NETWORK FOR RARE NEUROLOGICAL DISEASES (ERN-RND)

ERN-RND is a European Reference Network established and approved by the European Union. ERN-RND is a healthcare infrastructure which focuses on rare neurological diseases (RND). The three main pillars of ERN-RND are (i) network of experts and expertise centres, (ii) generation, pooling and dissemination of RND knowledge, and (iii) implementation of e-health to allow the expertise to travel instead of patients and families.

ERN-RND unites 64 of Europe's leading expert centres as well as 4 affiliated partners in 24 member states and includes highly active patient organizations. Centres are located in Austria, Belgium, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Netherlands, Poland, Slovenia, Spain and Sweden.

The following disease groups are covered by ERN-RND:

- Ataxias and Hereditary Spastic Paraplegias
- Atypical Parkinsonism and genetic Parkinson's Disease
- Dystonia, Paroxysmal Disorder and Neurodegeneration with Brain Iron Accumulation
- Frontotemporal Dementia
- Huntington's Disease and other Chorea
- Leukodystrophies

Specific information about the network, the expert centers and the covered diseases can be found on the network's website www.ern-rnd.eu.

Recommendation for clinical use:

The European Reference Network for Rare Neurological Diseases strongly recommends the use of the Consensus-based expert recommendations for diagnosis and clinical management of vanishing white matter.

DISCLAIMER

Clinical practice guidelines, practice advisories, systematic reviews and other guidance published, endorsed or affirmed by ERN-RND are assessments of current scientific and clinical information provided as an educational service.

The information (1) should not be considered inclusive of all proper treatments, methods of care, or as a statement of the standard of care; (2) is not continually updated and may not reflect the most recent evidence (new information may emerge between the time information is developed and when it is published or read); (3) addresses only the question(s) specifically identified; (4) does not mandate any particular course of medical care; and (5) is not intended to substitute for the independent professional judgement of the treating provider, as the information does not account for individual variation among patients. In all cases, the selected course of action should be considered by the treating provider in the context of treating the individual patient. Use of the information is voluntary. ERN-RND provided this information on an "as is" basis, and makes no warranty, expressed or implied, regarding the information. ERN-RND specifically disclaims any warranties of merchantability or fitness for a particular use or purpose. ERN-RND assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of this information or for any errors or omissions.

METHODOLOGY

The Consensus-based expert recommendations were endorsed by the Disease Group for Leukodystrophies of ERN-RND.

Disease group for Leukodystrophies:

Disease group coordinators:

Nicole Wolf¹, Kleopas Kleopa², Samuel Gröschel³

Disease group members:

Healthcare professionals:

Ales Tomek⁴, Ángel Martín⁵, Anna Ardisson⁶, Anna Fetta⁷, Anneli Kolk⁸, Aoife Mahony⁹, Arina Novasa¹⁰, Bart Dermaut¹¹, Beata Błażejewska-Hyżorek¹², Caroline Sevin¹³, Caterina Garone⁷, Christa-Caroline Bergner¹⁴, Daniel Boesch¹⁵, Dimitri Hemelsoet¹¹, Duccio Maria Cordelli⁷, Emmanuel Scalais¹⁶, Enrico Bertini¹⁷, Ettore Salsano⁶, Fran Borovecki¹⁸, Francesco Nicita¹⁷, Gessica Vasco¹⁷, Giacomo Garone¹⁷, Hanna Küpper³, Hans Hartmann¹⁹, Hendrik Rosewich³, Ieva Glazere¹⁰, Isabella Moroni⁶, Iwona Stępnia¹², Jacopo Sartorelli¹⁷, Johanna Uusimaa²⁰, Jørgen Erik Nielsen²¹, Karolina Ziora-Jakutowicz¹², Klára Brožová²², Laszlo Szpisjak²³, Lena Elisabeth Hjermand²¹, Leonardo Ulivi²⁴, Luca Solina⁷, Lucia Laugwitz³, Ludger Schöls³, Mar O'Callaghan²⁵, Marc Engelen¹, Mario Habek¹⁸, Marjo S. van der Knaap¹, Natalja Predkele¹⁰, Nicola Giannini²⁴, Odile Boespflug-Tanguy¹³, Pedro Oliva Nacarino²⁶, Peter Balicza²⁷, Pierre Kolber¹⁶, Pinar Topaloglu²⁸, Rachele Danti⁶, Rosa Cortese²⁹, Ruth Cutajar³⁰, Sabine Grønberg²¹, Susan Byrne⁹, Sylvia Boesch¹⁵, Thomas Klopstock³¹, Tim Rattay³², Tom de Koning³³, Veronica Di Pisa⁷, Wolfgang Koehler¹⁴

Patient representatives:

Sara Hunt³⁴, Tomasz Grybek³⁴

Affiliations:

1. Amsterdam UMC - Amsterdam University Medical Center, Netherlands.
2. Cyprus Institute of Neurology and Genetics, Egkomi, Cyprus.
3. University Hospital Tübingen, Germany.
4. Motol and Homolka University Hospital, Prague, Czech Republic.
5. La Paz University Hospital, Madrid, Spain.
6. IRCCS - Foundation of the Carlo Besta Neurological Institute, Milan, Italy.
7. IRCCS - Institute of Neurological Sciences of Bologna, Italy.
8. Tartu University Hospital, Estonia.
9. Irish Consortium: Tallaght University Hospital and Children's Health Ireland.
10. Pauls Stradins Clinical University Hospital, Riga, Latvia.
11. University Hospital Ghent, Belgium.
12. Institute of Psychiatry and Neurology, Warsaw, Poland.
13. APHP - Reference Centre for Leukodystrophies, Robert-Debré University Hospital, Paris, France.
14. University of Leipzig Medical Center, Germany.
15. Medical University Innsbruck, Austria.
16. CHL - Luxembourg Hospital Center, Luxembourg.

17. Pediatric Hospital Bambino Gesù, Rome, Italy.
18. University Hospital Center Zagreb, Croatia.
19. Hannover Medical School, Germany.
20. Finland Consortium: University Hospitals in Oulu, Tampere and Helsinki, Finland.
21. Rigshospitalet University Hospital Copenhagen, Denmark.
22. Thomayer University Hospital, Prague, Czech Republic.
23. Szent-Györgyi Albert Medical Center, Szeged, Hungary.
24. AOU - University Hospital Pisa, Italy.
25. Hospital Clinic Barcelona and Sant Joan de Déu Hospital, Barcelona, Spain.
26. Asturias Central University Hospital, Oviedo, Spain.
27. Semmelweis University, Budapest, Hungary.
28. Istanbul Faculty of Medicine, Turkey.
29. AOU - University Hospital Siena, Italy.
30. Mater Dei Hospital, Msida, Malta.
31. Ludwig Maximilian University Hospital, Munich, Germany.
32. University Hospital Schleswig-Holstein, Kiel, Germany.
33. University Medical Center Groningen, Netherlands.
34. ePAG representative.

Endorsement process:

- Proposal to endorse document – 23 February 2026
- Consent to endorse and publish document by whole ERN-RND disease group 24 June 2026
- Publication on ERN-RND webpage – 10 July 2026

REFERENCE

[van Voorst RJ, Schoenmakers DH, Bonkowsky JL, et al. Consensus-Based Expert Recommendations for Diagnosis and Clinical Management of Vanishing White Matter. *Neurology*. 2025;105\(11\):e214320. doi:10.1212/WNL.0000000000214320](#)

CONSENSUS-BASED EXPERT RECOMMENDATIONS FOR DIAGNOSIS AND CLINICAL MANAGEMENT OF VANISHING WHITE MATTER

© 2025 the authors

Source: <http://www.neurology.org/>

Link to publication: <https://www.neurology.org/doi/10.1212/WNL.0000000000214320>

The following content was reused in terms of Creative Commons CC-BY-NC-ND 4.0 license.

More information about Creative Commons licenses can be found on:

<https://creativecommons.org/licenses/list.en>

Consensus-Based Expert Recommendations for Diagnosis and Clinical Management of Vanishing White Matter

Romy J. van Voorst,^{1,2,*} Daphne H. Schoenmakers,^{1,2,3,*} Joshua L. Bonkowsky,^{4,5} Adeline Vanderver,^{6,7} Ingeborg Krägeloh-Mann,⁸ Geneviève Bernard,^{9,10,11} Enrico Bertini,¹² Ali Fatemi,¹³ Paulo V. Sgobbi,^{14,15} Nicole I. Wolf,^{1,2} Samuel Groeschel,⁸ Davide Tonduti,^{16,17} Caroline Sevin,¹⁸ Jennifer L. Orthmann-Murphy,⁷ Ludger Schöls,^{19,20} Ettore Salsano,²¹ Bernard Brais,²² Nicole Jaffe,^{23,24} Kasper W. ter Horst,²⁵ Sabine E. Hannema,^{26,27,28} Katherine G. Hayes,^{5,29} Jochen Meyburg,³⁰ Marc van Heerde,^{1,31} Anne Marie Sbrocchi,³² Rosalina van Spaendonck,³³ Isabelle Thiffault,^{34,35,36} Geesje H. Hofsteenge,³⁷ Carolina Sudmeier-Broek,³⁷ Corrie Timmer,^{25,37} Donna Skwirut,^{38,39} Allyson Buck,³⁹ Bret Hollberg,³⁹ Ron Chapeau,³⁸ Hanka Dekker,⁴⁰ Susan G. Campbell,⁴¹ Truus E.M. Abbink,^{1,2} Prisca S. Leferink,⁴² Marjo S. van der Knaap^{1,2,43}

Correspondence

Prof. van der Knaap
ms.vanderknaap@
amsterdamumc.nl

Neurology® 2025;105:e214320. doi:10.1212/WNL.00000000000214320

Abstract

Vanishing white matter (VWM) is a rare disorder, characterized by degeneration of CNS white matter, clinically often exacerbated by stressors such as fever and minor head trauma. VWM is caused by biallelic pathogenic variants in the *EIF2B1-5* genes, causing reduced activity of eukaryotic initiation of translation factor 2B, resulting in dysregulation of the integrated stress response (ISR). New scientific insights and increased clinical trials in experimental therapies highlight the need for clinical guidelines to improve and standardize care for patients with VWM worldwide. Standardized care is important for therapy development, as it lessens clinical variability of trial participants at study entry, enabling more sensitive evaluation of treatment outcomes. The aim of this study was to develop expert consensus-based recommendations for diagnosis and management of VWM. A real-time Delphi process with a multidisciplinary expert panel was conducted to formulate consensus-based recommendations. A literature review was performed to determine the strength of available evidence supporting each recommendation. The consensus yielded 43 recommendations on diagnosis, including genetic and MRI criteria, and on clinical management concerning disease progression, acute and long-term care, and preventive strategies. All known pathogenic and likely pathogenic *EIF2B1-5* variants were identified from the literature and Amsterdam Leukodystrophy Center laboratory. An overview of these *EIF2B1-5* variants was composed to facilitate diagnosis. Clinically used drugs may activate the ISR, posing a risk in VWM, or have no effect on or suppress the ISR, being probably safe in VWM. A second literature search explored the effects of clinically frequently used drugs on the ISR. Drugs were categorized into those likely to activate the ISR, suppress it, and have no likely effects on the ISR. Final judgment was achieved in a consensus meeting of experts. A patient management card was developed with input from clinical experts and patient advocates to provide information on these consensus-based recommendations in lay language and bridge the gap between scientific evidence and expert opinion on one side and the practical needs of clinicians and families on the other side. This study contributes to improving and standardizing VWM care based on scientific and expert insights, while highlighting key areas for future research.

MORE ONLINE

Supplementary Material

*These authors contributed equally to this work as co-first authors.

The Article Processing Charge was funded by the authors.

The Author affiliations appear at the end of the article.

This is an open access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

Copyright © 2025 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.

e214320(1)

Glossary

eIF2B = eukaryotic initiation of translation factor 2B; **ISR** = integrated stress response; **VWM** = vanishing white matter.

Introduction

Vanishing white matter (VWM, OMIM #603896) is a rare (estimated live birth incidence ~1:100,000) leukodystrophy characterized by diffuse cerebral white matter abnormalities with rarefaction and cystic decay.^{1,2} Patients can present at any age with chronic neurologic decline and additional subacute episodes of rapid neurologic deterioration provoked by stressors such as febrile infections.² Younger age at symptom onset is associated with more severe and rapid disease progression. In all patients, VWM is a devastating disease leading to premature death.²

In the past 3 decades, clinical studies, MRI, pathology, and fundamental research have increased understanding of the disease, paving the way for improved disease management. The pathomechanisms are not yet fully elucidated, but a dysregulated integrated stress response (ISR) caused by decreased activity of eukaryotic initiation factor 2B (eIF2B) due to biallelic pathogenic variants in any of the 5 eIF2B subunits drives the disease.^{3,4} Currently, there is no curative or disease-modifying treatment for VWM, although multiple therapeutic targets within the ISR have been identified. Two promising compounds, that is, guanabenz (EU Clinical Trials Register identifier: EudraCT 2027-001438-25, CTIS 2023-503320-89-00) and ABBV-CLS-7262 (fosigotifator, ClinicalTrials.gov identifier NCT05757141 and NCT06594016), activating eIF2B indirectly or directly, are currently under clinical investigation.

Emerging scientific insights and the increased implementation of clinical trials increase the need for clinical guidance to improve and harmonize care for patients with VWM globally. A study investigating the impact of VWM on 63 families confirmed this vital need for clear recommendations.⁵ Therefore, the aim of this study was to define consensus-based recommendations on the diagnosis and clinical management of VWM.

Methods

In 2019, an international consortium of 9 adult and pediatric neurologists, expert in leukodystrophies, especially VWM, was founded to facilitate diagnosis and therapy development in VWM.^{6–8} This clinical expert consortium initiated a real-time Delphi consensus procedure (April 5, 2024–June 1, 2024) to establish agreement on recommendations to guide clinical care in patients with VWM. We used a multistep approach consisting of the following: (1) expert and patient advocate consultation to identify the topics to be discussed in the eDelphi process and to formulate draft recommendations

(expert panel and patient advocates), (2) a systematic literature review to collect all available evidence substantiating or opposing the draft recommendations (R.J.v.V. and D.H.S.), (3) execution of the real-time Delphi procedure to agree on the recommendations (expert panel), and (4) agreement on the lay language material including a patient management card (VWM consortium and patient advocates).

Expert Panel

A total of 26 candidate panelists were invited to participate in the eDelphi process, of whom 25 accepted the invitation and 24 participated in voting. The expert panel consisted of the VWM consortium members (n = 9, A.V., J.L.B., I.K.-M., G.B., E.B., A.F., P.V.S., N.I.W., M.S.v.d.K.), supplemented with other pediatric and adult leukodystrophy experts (n = 6, S.G., D.T., C.S., J.L.O.-M., E.S., B.B.) and targeted specialists from relevant medical fields with experience with patients with leukodystrophy, including endocrinologists (n = 3, K.W.t.H., S.E.H., A.M.S.), pediatric gynecologist (n = 1, K.G.H.), geneticists (n = 2, R.v.S., I.T.), pediatric intensivists (n = 2, J.M., M.v.H.), and a complex care pediatrician (n = 1, N.J.). Panelists were asked to give input on the recommendations but could abstain from voting on statements on which they had insufficient expertise. An overview of the voting process is given in eTable 1. Dietitians (n = 3, G.H.H., C.S.B., C.T.) were consulted for the statements on dietary practices. A patient representative advisory board comprised 5 patient advocates representing different patient advocacy organizations, that is, VWM Families Foundation, United Leukodystrophy Foundation, and Vereniging Volwassenen, Kinderen en Stofwisselingsziekten.

Recommendations

This project focused on topics requiring VWM-specific recommendations. The topics and draft recommendations were identified in multiple video meetings and through the expert panel's written input, resulting in 43 draft recommendations. Input from patient advocates was incorporated during the drafting process. Recommendations on general supportive care for children and adults with disabilities were not part of this procedure.

Systematic Literature Review

A systematic literature search was performed to collect relevant evidence for the recommendations. The search strategy included a search string consisting of “vanishing white matter” and its synonyms, focusing on articles written in English and published after 2000. A PubMed search on November 10, 2023, identified 319 hits. Reference screening was performed to identify additional relevant articles. Title, abstract (Tiab), and full-text screening was performed independently by 2 researchers (R.J.v.V. and D.H.S.). The level of evidence was

determined for all included records, using a modified grading scheme⁹ because of the limited literature available for VWM (eTable 2). Relevant evidence from the included articles was extracted and organized in draft recommendations. The available evidence was tabulated for each draft recommendation, indicating whether it supported or opposed the recommendation. Eventually, 46 original articles were included. eFigure 1 presents a Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram of the literature search.

Clinically used drugs may activate the ISR, posing a risk for patients with VWM, or have no effect on or suppress the ISR, being probably safe for patients with VWM. A second systematic literature search was performed to investigate the effect of drugs frequently used in VWM on the ISR. Multiple search strings were combined for this search. The primary search string used the term “Integrated Stress Response” and its key components. This was combined with search strings for various drug classes and their synonyms. eFigure 2 presents details of the literature search using a methodology similar to that described above for the recommendations. Articles were reviewed, and final judgment was achieved in a consensus meeting with the VWM consortium and biomolecular scientists with ISR expertise (T.E.M.A. and S.G.C.). Eventually, 53 articles were included.

Real-Time Delphi Procedure

A real-time Delphi procedure was conducted using the software tool eDelphi 2024.¹⁰ All panelists received an overview of the draft recommendations with available literature evidence. Panelists were invited to indicate their level of agreement or disagreement using a 5-point Likert scale. They were encouraged to provide a rationale for their responses through an anonymous comment section during a 6–8-week period. Weekly reminders encouraged participation.

A plenary discussion with VWM consortium members ($n = 8$) and leukodystrophy experts ($n = 4$), held on April 26, 2024, led to the modification of 17 statements. All panelists were provided with the revised statements, minutes from the plenary discussion, and supplementary information regarding the pathophysiology of VWM. The modified statements were reintroduced into the eDelphi platform, and panelists were invited to vote again. Following typical Delphi procedures,¹¹ the percentage of consensus was calculated based on the agreeing and disagreeing votes (number of votes “strongly agree” + number of votes “agree”)/(total number of votes without the votes “neutral”). Neutral votes were interpreted as having no preference and, therefore, did not influence the percentage of consensus. However, if the neutral vote amounted to $\geq 25\%$ of the total panel votes, this reduced the strength of the recommendations. Statements were strongly recommended (A) if $\geq 75\%$ consensus was reached for “strongly agree,” with votes for “neutral” being $< 25\%$. Statements were recommended (B) if $\geq 75\%$ consensus was reached for “agree” or “strongly agree,” with votes for “neutral” being $< 25\%$. Statements were suggested (C) if $\geq 75\%$

consensus was reached for “strongly agree” or “agree,” but $\geq 25\%$ of the panel voted for “neutral.”

Statistical Analysis

Descriptive analysis was performed by R.J.v.V. and D.H.S. Percentages of agreeing and disagreeing responses in the eDelphi process were calculated to summarize the distribution of expert opinions.

Patient Management Card

The coordinating researchers (D.H.S. and R.J.v.V.) drafted the lay language material, including a visual representation of the recommendations. The leaflet was further refined based on several rounds of written input from patient advocates and VWM consortium members. The final contents and leaflet design were agreed upon in an online meeting of the VWM consortium.

Variant Update

We listed all known pathogenic and likely pathogenic variants in *EIF2B1-5* genes reported since the 2010 last variant update¹² up to October 2024, supplemented by variants from the VWM database of the Amsterdam Leukodystrophy Center and an extensive literature search using the Franklin Tool.¹³

Standard Protocol Approvals, Registrations, and Patient Consents

This study did not involve human participants or identifiable personal data. Therefore, approval by an institutional review board was not required.

Data Availability

Raw data of the eDelphi voting may, after approval of those involved, be shared at the request of any qualified investigator for purposes of replicating procedures and results.

Results

Table 1 provides an overview of all recommendations. eTable 3 provides their strength, substantiating evidence, and degree of agreement. eTable 4 details the votes in the eDelphi procedure and the resulting classification. The following sections elaborate on the main considerations and points of discussion.

Diagnosis

There was majority agreement that the diagnosis of VWM is based on a combination of clinical features, brain MRI characteristics, and genetic confirmation. MRI characteristics of VWM are listed in Table 2 and illustrated in Figures 1 and 2. Recognizing VWM on brain MRI may be challenging, requiring referral to a leukodystrophy expert center for MRI assessment. In the case of uncertain genotypes, MRI and clinical assessment by a VWM expert were regarded as the best next step to determine whether the patient has VWM. MRI is considered most helpful in determining whether the

patient has VWM if 1 pathogenic or likely pathogenic variant is found in a patient. In patients with a suspected VWM diagnosis based on a typical MRI and a single pathogenic or likely pathogenic variant in a single *EIF2B1-5* gene, attempting to identify a second variant in trans, even if of uncertain significance, was considered necessary, for example, by Sanger sequencing, cDNA analysis, array comparative genomic hybridization, multiplex ligation-dependent probe amplification, and long-read genome sequencing. Most known pathogenic variants are missense, and biallelic null variants have not yet been described. Therefore, if the MRI pattern is consistent with VWM but no pathogenic or likely pathogenic variant in *EIF2B1-5* is found, it is unlikely that the patient has VWM and another diagnosis should be looked for. In this case, mitochondrial leukoencephalopathies constitute the most likely alternative (Table 2). Several diseases may clinically mimic VWM. An overview is provided in eTable 5. A detailed overview of all known genotypes associated with VWM is provided in eTable 6.

Prediction of Disease Course

Full agreement was reached on disease course prediction. Key predictors include age at onset and genotype,^{2,17,18} of which age at onset is the strongest predictor. Typically, earlier onset is associated with faster disease progression. A previous natural history study showed that, especially for onset before the age of 4 years, earlier onset was associated with faster disease progression.² It is important to note that other factors co-determine the disease course, such as the presence of ISR stressors. With longer disease duration, the occurrence of such factors becomes more likely, contributing to increasing disease variability.² It was noted that these stressors constitute a risk of triggering an episode of acute decline, but that such an episode does not always follow. Prediction by genotype is hampered by disease variability, also between siblings, and by the lack of comprehensive information in the case of novel variants, which frequently occur.

Measures to Prevent Episodes of Rapid Decline

Stressors activating the ISR^{2,19,20} provoke episodes of acute decline, which negatively affect the disease course and outcome.² Therefore, the importance of implementing preventive measures to avoid ISR-activating stress factors was recognized. However, possible constraints on the quality of patients' lives related to preventive measures were also recognized. Therefore, discussing benefits and disadvantages associated with such measures with patients and families in individual cases is essential.

Antipyretics

Fever activates the ISR, and febrile infections are the most common triggers for acute decline in patients with VWM.² Most agreed that measures to avoid and treat fever are indicated. The antipyretic of first choice, as potent and safe, would be ibuprofen or naproxen, to be combined with paracetamol/acetaminophen, if necessary. Age-based limitations and other risk factors to the use of these antipyretics in

individual patients should be considered, and final antipyretic choices should be made on a case-by-case basis.

Antibiotics

When a patient presents with a febrile condition, efforts should be made to determine whether antibiotics are required. In cases where a bacterial infection is suspected but not confirmed, there was consensus that a lower threshold for initiating antibiotics should be considered compared with patients without VWM. It was, however, emphasized that in cases of frequent infections, consultation with an infectious disease specialist or immunologist could be valuable, and that before considering prophylactic antibiotics, nonantibiotic approaches should be explored.²¹

Vaccinations

There was complete consensus that although vaccinations may sometimes induce acute decline,² the risk associated with an infection is much higher than with the respective vaccination. Therefore, routine vaccinations, as well as vaccinations against COVID-19 and influenza, were recommended for patients with VWM. Recommendations for antipyretic use during vaccinations to avoid fever should be based on the type of vaccine, considering the likelihood of inducing fever and the expected duration of such fever.

Head Trauma

It was agreed by all that minor head trauma, the second most common trigger for acute decline in VWM,² should be avoided as much as reasonably possible without unduly restraining patients' activities of daily life.

Surgical Procedures

All agreed that surgical procedures in VWM require caution. Noninvasive options are preferred when possible, and the risk of perioperative infection should be minimized.

Behavioral Management

Apart from acute severe fright, psychological stress is not known to provoke acute decline. Avoiding psychological stress may lead to spoiling and cause behavioral difficulties. We, therefore, recommend standard behavioral management.

Medication

Although clinical evidence in patients is unavailable for most drugs, it was agreed that drugs that may activate the ISR should be avoided, if possible, because in VWM, the rapid decline is provoked by ISR activation. Clinical evidence for provoking decline is only present for anesthetics: anesthesia was a provoking factor in 16% of the patients with episodes of acute decline.² Inhalation anesthetics, such as sevoflurane, which are most commonly used to induce anesthesia in children, are known to activate the ISR and may pose a risk for patients with VWM (Table 3, eTable 7). It is, therefore, recommended to consider using alternative anesthetic agents, such as propofol, which do not affect the ISR. The risk is more theoretical and not based on clinical evidence for other drugs.

Table 1 Consensus-Based Recommendations

Number	Strength	Recommendation	Agreement (%)
Diagnosis (avoiding false-negative and false-positive diagnoses)			
1.1	A	Genetic confirmation should always be sought after suspected VWM diagnosis based on brain MRI findings	100
1.2	B	If a brain MRI is consistent with VWM (in description), the diagnosis of VWM is confirmed by the presence of 2 pathogenic or likely pathogenic variants or variants of unknown significance in one of the <i>EIF2B1-5</i> genes	100
1.3	A	If a brain MRI is consistent with VWM (in description) and a single pathogenic or likely pathogenic variant or variant of unknown significance is found in one of the <i>EIF2B1-5</i> genes, we recommend extra efforts to identify a second variant in the same gene	100
1.4	A	If a brain MRI is consistent with VWM and no (likely) pathogenic variants or variants of unknown significance in one of the <i>EIF2B1-5</i> genes can be found, we recommend searching for another cause	100
1.5	A	If variants in one of the <i>EIF2B1-5</i> genes are found in a patient, we recommend evaluation of a recent brain MRI to help determine a diagnosis of VWM.	100
1.6	A	When an index patient is diagnosed, we recommend genetic counseling to discuss family screening and family planning	100
Prediction of disease course			
2.1	A	Disease course can be predicted for age at onset younger than 4 years based on age at first signs, except for developmental delay	100
2.2	A	Known gene variants can help predict the disease course	100
2.3	A	Episodes of acute decline predict a worse disease course	100
2.4	A	Seizures predict a worse disease course	100
2.5		We suggest counseling families on predicted disease course based on the following statements	
2.5.1	A	A lower age at symptom onset is associated with a faster and more severe deterioration	100
2.5.2	B	Genotype is predictive of the phenotype	100
2.5.3	A	Factors known to precipitate episodes of rapid decline should be avoided because such episodes are associated with a more severe disease course	100
2.5.4	A	Treatment of epilepsy and seizures is important because patients with seizures have a more severe disease course	100
Measures to prevent episodes of rapid decline			
3.1	A	In the case of fever, we recommend the prompt use of antipyretics aiming at normal temperature	94
3.2	A	In the case of a febrile infection, we recommend close follow-up and to consider early use of antibiotics	100
3.3	B	In the case of recurrent and documented bacterial infections, prophylactic antibiotics can be considered in consultation with infectious diseases and/or immunology	100
3.4	B	We recommend vaccination according to the regular national vaccination program, provided that antipyretics are given to avoid fever as much as possible	100
3.5	A	We specifically recommend vaccination against frequent infections, such as influenza and COVID-19	100
3.6	A	We recommend wearing a helmet for daily-life activities associated with enhanced risk of head trauma, such as bicycling	100
3.7	B	We recommend avoiding sports activities associated with enhanced risk of head trauma	100
3.8	A	We recommend balancing the need for major surgical procedures against the risk of anesthesia and physical stress related to the procedure. PEG tube placement is a minor surgery	100
3.9	A	In general, consideration should be given to nonsurgical alternatives for major surgery	100
3.10	A	In general, consideration should be given to alternatives for the implantation of a foreign body enhancing the risk of infection	100
3.11	A	We recommend discussing infection prevention and close monitoring with the surgical and anesthesiology team before surgical procedures	100
3.12	B	We recommend avoiding catabolism	100
3.13	A	We suggest close monitoring after head trauma, surgical procedures, and the use of anesthetics	100

Continued

Table 1 Consensus-Based Recommendations (continued)

Number	Strength	Recommendation	Agreement (%)
3.14	A	In the case of previous acute severe decline, we recommend considering hospital admission with high care possibility when a similar stressor occurs	100
3.15	B	Apart from acute severe fright, psychological stress is not known to provoke acute decline; we, therefore, recommend standard behavioral management	100
Medication			
4.1	B	We recommend avoiding drugs that activate the integrated stress response, because they may trigger rapid decline	88
4.2	A	If the drug of choice may activate the integrated stress response and there is no good alternative, the risk of the drug should be weighed against the risk or impact of the problem, which instigated the drug	100
Acute presentation management			
5.1	A	We recommend to start with antipyretics in the case of fever aiming at normal temperature	95
5.2	A	We recommend to consider treatment with antibiotics in the case of fever	89
5.3	A	We recommend to consider hospital admission with high care possibility in the case of acute neurologic decline	100
5.4	C	We recommend considering to start with corticosteroids in the case of acute severe neurologic decline (e.g., reduced level of consciousness and loss of ability to walk), if there is no contraindication	100
Chronic disease management: epilepsy			
6.1.1	A	We recommend to start maintenance anticonvulsant treatment in the case of a (likely) seizure, even after a single event	83.33
Chronic disease management: nutrition			
6.2.1	A	We recommend to maintain a good nutritional status and use (PEG) tube feeding when sufficient oral intake cannot be guaranteed	100
Chronic disease management: ovarian insufficiency and bone health			
6.3.1	A	Because ovarian insufficiency is a common feature in female patients with VWM, we recommend referral to an endocrinologist in the case of primary amenorrhea at the age of 15 or secondary amenorrhea at any age	100
6.3.2	A	We recommend to counsel female patients about the consequences of estrogen deficiency regarding fertility, osteoporosis, and sexual health	100
6.3.3	A	We recommend to monitor risk factors of osteoporosis and refer to an endocrinologist when present	100
Chronic disease management: pregnancy and delivery			
6.4.1	A	We recommend close monitoring of female patients with VWM during pregnancy	100
6.4.2	A	We recommend delivery in a health care setting with obstetrics, neurology and intensive care unit present, and close postpartum monitoring in the case of a pregnant patient with VWM	100

Abbreviations: COVID-19 = coronavirus disease 2019; PEG = percutaneous endoscopic gastrostomy; VWM = vanishing white matter. Percentage of consensus is calculated as (number of votes “strongly agree” + number of votes “agree”)/(all votes without the votes “neutral”). Statements were strongly recommended (A) if ≥75% consensus was reached for “strongly agree,” without counting votes for “neutral,” with votes for “neutral” being <25%. Statements were recommended (B) if ≥75% consensus was reached for “agree” or “strongly agree,” without counting votes for “neutral” and with votes for “neutral” being <25%. Statements were suggested (C) if ≥25% of the panel voted for “neutral” and, without counting neutral votes, ≥75% consensus was reached for “strongly agree” or “agree.”

When choosing medications, it is important to weigh the risks and benefits carefully, consider non-ISR activating alternatives, and base decisions on available evidence and the clinical need for a particular class of drugs in an individual participant.

Acute Presentation Management

It was agreed that antibiotics and antipyretics should be considered in cases of acute neurologic decline, particularly when the trigger is a febrile infection. The use of corticosteroids is controversial, because the available evidence for an ameliorating effect is anecdotal.²²⁻²⁴ According to the panel,

the potential benefits of corticosteroid use may outweigh the potential risks, if their use is limited to a short period. This is the only recommendation with strength C.

Chronic Disease Management

Epilepsy

Adequate treatment of epilepsy is recommended because seizures may trigger rapid deterioration in VWM and have a negative impact on the disease course.² In children, careful adjustment of antiseizure medications according to weight is

Table 2 Brain MRI Characteristics

VWM phenotype	MRI characteristics	Differential diagnosis
Neonatal and early infantile VWM (onset ≤1 y of age)	• Cerebral white matter is more hyperintense than unmyelinated white matter on T2W images, without or with little rarefaction or cystic decay • Diffusion restriction, if present, involves relatively spared white matter • The abnormal white matter may look swollen • Gyration may be immature • Often anterior temporal cysts • Sometimes pontocerebellar hypoplasia • Diffusely abnormal cerebral white matter signal intensity that increasingly resembles CSF signal (decreased signal on T1W and T2 FLAIR images, increased signal on T2W images) • Rapidly progressive white matter loss leading to a severely destructed brain white matter • Sometimes, ventricular dilatation occurs with only a rim of white matter under the remaining cortex. May be associated with macrocephaly	• Aicardi-Goutières syndrome: calcifications are often, but not invariably present • Congenital CMV infection: calcifications are often, but not invariably present. Cortical dysplasia may occur. Follow-up MRI looks better • Canavan disease: cerebral white matter is extensively affected but periventricular white matter and corpus callosum are typically spared. Involvement of the globus pallidus and thalamus is seen while caudate nucleus and putamen are spared. Restricted diffusion is present in affected structures
Late-infantile and early-childhood VWM (onset 1–4 y of age)	• Initially swollen aspect of cerebral white matter that is more hyperintense than unmyelinated white matter on T2W images, without or with little rarefaction or cystic decay • Diffusion restriction, if present, involves relatively spared white matter • Diffusely abnormal cerebral white matter signal intensity that increasingly resembles CSF signal, (decreased signal on T1W and T2 FLAIR images, increased signal on T2W images) • Cystic cerebral white matter degeneration is typically diffuse and not well delineated • Radiating stripes, hyperintense within hypointense cerebral white matter on T2 FLAIR and T2W images, due to relatively preserved perivascular tissue strands • Rapidly progressive white matter loss leading to a severely destructed brain • Sometimes, the decayed cerebral white matter looks swollen, with progressive macrocephaly	• Mitochondrial leukoencephalopathy: may be indistinguishable from early-onset VWM with cystic cerebral white matter decay, but the cysts tend to be better delineated, the diffusion restriction occurs often in rims of cysts, and there is multifocal contrast enhancement. MR spectroscopy may reveal (highly) elevated lactate. Additional lesions in basal nuclei and thalami are common • Aicardi-Goutières syndrome: calcifications are often, but not invariably present. Diffuse cystic decay of the cerebral white matter does not occur • Canavan disease: cerebral white matter is extensively affected but periventricular white matter and corpus callosum are typically spared. Involvement of the globus pallidus and thalamus is seen while caudate nucleus and putamen are spared. Restricted diffusion is present in affected structures • Megalencephalic leukoencephalopathy with subcortical cysts: diffusely swollen cerebral white matter with megalencephaly; the corpus callosum is spared. The cysts are subcortical and not related to rarefaction or cystic decay. Diffusion is increased in all affected white matter
Juvenile VWM (onset 4–18 y of age)	• “Classic” VWM MRI with diffuse cerebral white matter abnormality • Progressive cerebral white matter rarefaction and cystic decay • Radiating stripes, hyperintense within hypointense white matter on T2 FLAIR and T2W images in cerebral white matter due to relatively preserved perivascular tissue strands • White matter signal intensity increasingly resembles CSF signal (decreased signal on T1W and T2 FLAIR images, increased signal on T2W images). This rarefaction/cystic white matter degeneration is typically diffuse and there are no well-delineated cysts • Involvement of the inner rim of the corpus callosum • Diffusion restriction, if present, involves relatively spared white matter • Signs of astrocytic gliosis (increased signal on T2 FLAIR and T2W images and mildly decreased signal on T1W images) may be present • Some cerebral white matter atrophy may occur	• Mitochondrial leukoencephalopathies: May be indistinguishable from VWM with cystic cerebral white matter decay, but cysts are typically multifocal, well delineated. Multifocal white matter contrast enhancement and diffusion restriction are frequent. Typically, the middle layer of the corpus callosum is affected. Brainstem abnormalities are common. MR spectroscopy reveals (highly) elevated lactate. Additional lesions in basal nuclei and thalami are common • Metachromatic leukodystrophy: no rarefaction or cystic decay. All layers of the corpus callosum are affected, typically starting with a central splenial lesion. Often a tigroid pattern with radiating hypointense stripes within hyperintense white matter on T2 FLAIR and T2W images reflecting relative preserved perivascular myelin and lipid storage. Diffusion restriction mostly in the stripes • Krabbe disease: no rarefaction or cystic decay. All layers of the corpus callosum affected. Tigroid pattern with radiating hypointense stripes within hyperintense white matter on T2 FLAIR and T2W images reflecting relative preserved perivascular myelin and lipid storage. Diffusion restriction mostly in the stripes. Contrast enhancement of cranial nerves may occur • Alexander disease: predominantly frontal white matter hyperintensities on T2W images. Localized and well-delineated white matter cysts may occur. Signal abnormality of basal nuclei and thalami are frequent. Brainstem lesions occur, typically in the medulla. Contrast enhancement may be seen in localized lesions • Canavan disease: cerebral white matter is extensively affected, but periventricular white matter and corpus callosum are typically spared. Involvement of the globus pallidus and thalamus is seen, but the caudate nucleus and putamen are spared. Restricted diffusion in affected structures • Megalencephalic leukoencephalopathy with subcortical cysts: diffusely swollen cerebral white matter with megalencephaly; corpus callosum is spared. Cysts are subcortical and not related to rarefaction or cystic decay. Diffusion is increased in all affected white matter • Multiple sclerosis: lesions can be cavitory but are typically multifocal, asymmetrical, and located in juxtacortical and periventricular regions

Continued

Table 2 Brain MRI Characteristics (continued)

VWM phenotype	MRI characteristics	Differential diagnosis
Adult VWM (onset ≥18 y of age)	• Extensive cerebral white matter signal abnormalities, but they may be patchy instead of diffuse • Rarefaction and cystic decay are mild or absent • Signs of astrocytic gliosis (increased signal on T2 FLAIR and T2W images and mildly decreased signal on T1W images) • Increased diffusion • Involvement of the inner rim of the corpus callosum • Progressive white matter atrophy	• Vascular disease, microangiopathy: may be difficult to distinguish from adult VWM. Next to cerebral white matter lesions, typically also lesions in the basal ganglia and brainstem (most helpful distinguishing item). The corpus callosum is typically spared. Microbleeds may occur. Cavitation, if present, is well delineated. Diffusion restriction may occur in fresh infarcts • Metachromatic leukodystrophy: may be difficult to distinguish from adult VWM. Typically, no rarefaction or cystic decay. All layers of the corpus callosum are affected. There may also be cerebral white matter atrophy and gliosis • Adult-onset leukoencephalopathy with axonal spheroids and pigmented glia: cerebral white matter abnormality is typically asymmetrical and patchy with a frontal predominance. Diffusion restriction in small lesions with a steppingstone appearance
Episode of acute decline	• Signal abnormalities in basal nuclei, thalami, and brainstem, in addition to the cerebral white matter abnormalities • If the patient survives, the lesions improve or may disappear • No cystic evolution of these lesions	• Mitochondrial leukoencephalopathies: the combination of cerebral white matter abnormalities and lesions in basal nuclei, thalami, and brainstem may be indistinguishable from VWM. However, in mitochondrial disease, the cysts are typically well delineated and may also affect basal nuclei and thalami. Multifocal white matter contrast enhancement and diffusion restriction are frequent. MR spectroscopy reveals (highly) elevated lactate • Alexander disease: predominantly frontal white matter hyperintensities on T2W images. Localized white matter cysts may occur. Signal abnormalities of basal nuclei and thalami are frequently observed. Brainstem lesions occur, often in medulla. Contrast enhancement may occur in localized lesions

Abbreviations: FLAIR = fluid-attenuated inversion recovery; T1W = T1-weighted; T2W = T2-weighted; VWM = vanishing white matter. This table is based on Refs. 14–16. More information on the natural history of MRI changes in VWM, including images, can be found in Ref. 14. More information on basal ganglia abnormalities associated with episodes of acute decline can be found in Ref. 15. Horizontal stripe indicates findings typical in early (above) and advanced (below) disease stages.

recommended. It was mentioned that preventive start of anticonvulsants could be considered in patients with severe forms of VWM with onset before 1 year, such as a Cree leukoencephalopathy.

Nutrition

Previous research has shown that amino acid deprivation triggers the ISR in vitro.^{19,20} This raises the question whether fasting and/or vomiting could induce an episode of acute decline in VWM through amino acid deprivation. However, studies on basic physiology indicate that short-term fasting does not lead to significant cellular or blood amino acid depletion.²⁵ During short-term fasting, homeostatic mechanisms, such as muscle protein degradation, provide sufficient amino acids. Clinical observations align with this, as acute episodes of decline in patients with VWM have not been reported after short fasting periods, such as overnight fasting.

With prolonged fasting or malnutrition, systemic levels of various amino acids may decrease,²⁶ potentially triggering the ISR in patients with VWM. Therefore, maintaining adequate long-term nutritional status is strongly recommended in managing VWM. If oral intake is inadequate, tube feeding with complete formula should be considered. Ensuring good nutritional status is a standard medical practice in both acute and chronic illnesses^{27–29} and may be particularly important in VWM to prevent amino acid deprivation–induced ISR activation. There is no evidence to support the administration of additional enteral or intravenous amino acid supplementation.

Ovarian Insufficiency and Bone Health

VWM is frequently associated with ovarian insufficiency in women,² and measures to treat and monitor its consequences are recommended. Evaluation of the menstrual cycle at follow-up visits helps to identify ovarian insufficiency. Conforming to established osteoporosis prevention and management guidelines, it was unanimously agreed that all risk factors of osteoporosis such as age, mobility, nutritional status, calcium, vitamin D, and estrogen status should be considered.^{30,31} Estrogen deficiency is also known to affect cardiac health, so counseling should be performed as appropriate.³²

Pregnancy and Delivery


It was agreed that obstetric care deserves specific attention because pregnancy and delivery may trigger acute deterioration peripartum or postpartum.^{33–35} Extra attention to potential triggering factors as described in recommendation section 3 is recommended.

Patient Management Card

A patient management card summarizing the most important recommendations is provided in eFigure 3, A and B.

Discussion

This study provides a consensus-based guideline for the diagnosis and clinical management of VWM according to the latest scientific and expert insights. Using a real-time eDelphi method, we developed recommendations that address key


Figure 1 Brain MRI Characteristics

(A-E) Typical MRI findings per VWM subtype (increasing age at onset from top to bottom) and for early disease stage (left panel) or advanced disease stage (right panel) on T2 FLAIR images. A description of the corresponding MRI abnormalities is provided in Table 2. (F) Hyperintensities on T2-weighted images in the midbrain, basal ganglia, and thalami associated with an acute episode (left panel), which spontaneously resolved after 6 months (right panel). FLAIR = fluid-attenuated inversion recovery; VWM = vanishing white matter.

challenges health care providers, patients, and families face. The criteria for recommendations were rather strict: if $\geq 25\%$ of the votes were “neutral,” the strength was a C, even if the majority vote favored the statement. The only class C voting

outcome was for using corticosteroids in the case of acute decline. The recommendations on diagnosis stress the importance of combining MRI criteria with genotype information to enhance diagnostic accuracy. The

Figure 2 Unusual MRI Findings in VWM



(A) Presymptomatic patient with bilateral confluent hyperintensities on T2 FLAIR images in the periventricular and deep cerebral white matter and inner rim of the corpus callosum, sparing the subcortical white matter and without rarefaction or cystic decline of the affected white matter. (B) Anterior temporal cysts in a patient with neonatal VWM. (C) Hydrocephalus with ventriculomegaly in a patient with neonatal presentation. (D) Severe atrophy due to loss of cerebral white matter, leading to ventriculomegaly. (E) Extensive diffusion restriction in the cerebral white matter and internal capsule, with high signal on the DWI and low signal on the ADC maps. Only the frontal deep white matter that is mildly rarefied on T2 FLAIR imaging has an increased diffusion. ADC = apparent diffusion coefficient; DWI = diffusion-weighted imaging; FLAIR = fluid-attenuated inversion recovery; VWM = vanishing white matter.

recommendations for acute and long-term management of VWM guide clinical practice for this disease. The patient management card may support patients and their families during high-stress situations, providing guidance and trust in care management.

The VWM consortium, in collaboration with patient advocacy groups, is working on various projects to improve and harmonize research and care in VWM.^{6,7,36} The rarity of VWM requires global collaboration in research studies, so there is a pressing need for uniform clinical standards.^{2,7} In a global qualitative and quantitative study about the impact of VWM, families stressed the need for comprehensive clinical guidance.⁵ By providing this clinical guidance, consistent management of VWM worldwide can be improved, benefiting both current care and future (therapeutic) studies.

The management of VWM is characterized by efforts to find the individual balance between avoidance of stressors and participation in regular life activities. Preventive measures for an episode of rapid neurologic deterioration may have a huge impact on patients and their families.⁵ The panel emphasized

the importance of having informed discussions with families to balance quality-of-life goals with the risk of a potential episode of decline. It is important to emphasize that these recommendations serve as recommended and suggested general guidelines, and decisions should always be made on an individual basis. This allows for personalized management strategies that are tailored to the specific needs of each patient and their family.³⁷

A significant evidence gap exists regarding medications. The recommendations on using or avoiding certain medications are primarily informed by fundamental research on the ISR, and we acknowledge that supporting clinical evidence is limited.² Clinical exposure experiments to determine the risk of provoking an episode of rapid decline in humans would be unethical. The currently available VWM animal models mimic the phenotype of chronic decline, but acute stress-provoked episodes have not yet been modeled,³⁸⁻⁴⁰ hampering research on these episodes. Uncertainty exists about the use of corticosteroids during episodes of acute neurologic decline. Acknowledging these limitations, the panel has classified the recommendation on corticosteroids as level C (suggested

Table 3 List of Clinically Used Drugs That Were Investigated for Their Effect on the ISR

Drug type	Name	Study design	Cell/tissue/organ/species	Effect on the ISR
Anesthetic	Isoflurane ^{ISR act}	In vivo/in vitro	Rat hippocampus	↑ATF4, CHOP, p-eIF2α
		In vivo	Yeast	↑ATF4, p-eIF2α
Anesthetic	Sevoflurane ^{ISR act}	In vivo/in vitro	Mice hippocampus	↑ATF4, CHOP, p-eIF2α
		In vivo/in vitro	Mouse pups cerebral cortex	↑ATF4, CHOP, p-eIF2α
Anesthetic	Halothane ^{ISR act}	In vivo	Rat liver cells	↑p-eIF2α, ↓eIF2B activity
Anesthetic	Lidocaine ^{ISR act}	In vitro	Neuroblastoma cell line	↑ATF4, CHOP
Anesthetics	Lidocaine ^{ISR act} , ropivacaine ^{ISR act} , levobupivacaine ^{ISR act} , bupivacaine ^{ISR act} , prilocaine ^{ISR act} , chloroprocaine ^{ISR act}	In vitro	Osteosarcoma cell line	↑ATF4, p-eIF2α
Anesthetic	Propofol + intralipid emulsion ^{ISR inh}	In vivo	Neuroblastoma cell line, experience in patients with VWM	↓ATF4
Antacid	Omeprazole ^{ISR quest}			No evidence
Antacid	Esomeprazole ^{ISR quest}			No evidence
Antibiotic	Azithromycin ^{ISR act}	In vitro	Rat adrenal gland cell line; fibrosarcoma cell line	↑ATF4, CHOP, p-eIF2α
Antibiotic	Doxycycline ^{ISR act}	In vitro	Human colon adenocarcinoma cell line; human hepatocytes; breast cancer cell line	↑ATF4, CHOP
		In vitro	Mouse kidney and liver tissue	↑ATF4, CHOP, p-eIF2α
Antibiotic	Minocycline ^{ISR quest}			Inconclusive results
Antidepressant	Fluoxetine ^{ISR quest}			Inconclusive results
Antidepressant	Vortioxetine ^{ISR inh}	In vivo/in vitro	Rat hippocampal and cortical tissues	↓ATF4, CHOP, p-eIF2α
Antidepressant	Trazodone ^{ISR inh}	In vivo/in vitro	Chinese hamster ovary cell line	↓ATF4, CHOP
Antiepileptic	Carbamazepine ^{ISR act}	In vitro	Human and mouse primary hepatocytes	↑ATF4, CHOP
Antiepileptic	Valproic acid ^{ISR quest}			Inconclusive results
Antiepileptic	Phenobarbital ^{ISR quest}			No evidence
Antiepileptic	Lamotrigine ^{ISR quest}			No evidence
Antiepileptic	Levetiracetam ^{ISR quest}			No evidence
Antiepileptic	Vigabatrin ^{ISR quest}			No evidence
Antihypertensive	Propranolol ^{ISR quest}			No evidence
Antihypertensive	Valsartan ^{ISR quest}			Inconclusive results
Antipsychotic	Haloperidol ^{ISR quest}			No evidence
Antipsychotic	Olanzapine ^{ISR act}	In vivo/in vitro	Neuroblastoma cell line; rat hypothalamus	↑ATF4, p-eIF2α
Antipsychotic	Clozapine ^{ISR act} , haloperidol ^{ISR act} , olanzapine ^{ISR act}	In vivo/in vitro	Immortalized human hepatocyte cell line; rat liver	↑ATF4, CHOP

Continued

Table 3 List of Clinically Used Drugs That Were Investigated for Their Effect on the ISR (continued)

Drug type	Name	Study design	Cell/tissue/organ/species	Effect on the ISR
Antipsychotic	Thioridazine ^{ISR act}	In vivo/in vitro	Mouse colorectal cancer cell line	↑ATF4, CHOP, p-eIF2α
Antipyretic	Acetaminophen ^{ISR act} /paracetamol ^{ISR act}	In vivo/in vitro	Luciferase transgenic mice	↑ATF4, CHOP, p-eIF2α in chronic high treatment for 18 days
Antipyretic	Aspirin ^{ISR quest}			Inconclusive results
Antipyretic	Sodium salicylate ^{ISR quest}			Inconclusive results
Corticosteroid	Dexamethasone ^{ISR inh}	In vitro	Human trabecular meshwork cells	↓ATF4, CHOP
Corticosteroid	Methylprednisolone ^{ISR quest}			No evidence
Corticosteroid	Prednisolone ^{ISR quest}			No evidence
NSAID	Ibuprofen ^{ISR quest}	In vitro	Neuroblastoma cell line	Inconclusive results
NSAID	Naproxen ^{ISR quest}	In vitro	Skin carcinoma cell line	Inconclusive results
NSAID	Diclofenac ^{ISR act}	In vitro	Human and mouse primary hepatocytes	↑ATF4, CHOP
NSAID	Indomethacin ^{ISR act}	In vitro	Primary gastric mucosal cell line	↑ATF4, CHOP
NSAID	Indomethacin ^{ISR act} /diclofenac ^{ISR act}	In vitro	Colorectal adeno-carcinoma cell line	↑ATF4, CHOP, p-eIF2α
NSAID	Celecoxib ^{ISR act}	In vitro	Gastric carcinoma cell line	↑ATF4, CHOP, p-eIF2α
		In vitro	Liver tumor cell line	↑ATF4, CHOP
NSAID	Tolfenamic acid ^{ISR act}	In vitro	Colorectal cancer cell line	↑ATF4, CHOP
Opioid	Morphine ^{ISR act}	In vivo/in vitro	Rat dorsal root ganglions	↑ATF4, CHOP
Opioid	Oxycodone ^{ISR act}	In vivo/in vitro	Rat nucleus accumbens, cortex and brainstem; breast cancer cell line	↑ATF4, p-eIF2α
		In vivo/in vitro	Rats whole brain tissue; breast cancer cell line	↑ATF4, CHOP, p-eIF2α
Opioid	Sufentanil ^{ISR quest}	In vivo/in vitro	Rat hepatic ischemia/reperfusion model	Inconclusive results
Sedative	Alimemazine ^{ISR quest}			No evidence
Sedative	Dexmedetomidine ^{ISR quest}			Inconclusive results
Sedative	Diazepam ^{ISR quest}			No evidence
Sedative	Clonazepam ^{ISR quest}			No evidence
Sedative	Clobazam ^{ISR quest}			No evidence
Sedative	Midazolam ^{ISR quest}			Inconclusive results
Sedative	Oxazepam ^{ISR quest}			No evidence
Sedative	Temazepam ^{ISR quest}			No evidence
Spasmolytic	Baclofen ^{ISR neutr}	In vitro	Primary rat retinal ganglion cells	↓ATF4, CHOP, p-eIF2α, but does not readily cross BBB

Abbreviations: BBB = blood brain barrier; ISR = integrated stress response; VWM = vanishing white matter; CHOP = C/EBP homologous protein; p-eIF2α = phosphorylated eukaryotic initiation factor 2 alpha; ATF4 = activating transcription factor 4 .
ISR act = ISR activating; ISR inh = ISR inhibiting; ISR quest = ISR effect not investigated or equivocal findings; ISR neutr = neutral. References are provided in eTable 7 online.

practice). Further research is necessary to establish optimal treatment strategies.

Relying on limited evidence and expert opinions is inevitable in a disease as severe and rare as VWM. The real-time eDelphi methodology enabled us to align expert opinions from a diverse international panel. However, inherent to the eDelphi method are potential biases due to panel selection. Panel members have diverse experience with VWM, which may have influenced the outcomes. Nevertheless, similar clinical guidance documents have found to be helpful in other leukodystrophies.⁴¹ Continued international collaboration and expert alignment are crucial until evidence gaps are addressed.^{42,43}

In conclusion, this study guides the diagnosis and care of patients with VWM. It helps to bridge the gap between limited scientific evidence and the practical needs of clinicians and families. The consensus-based recommendations are an important step toward harmonizing global care for VWM, which should improve patient outcomes and quality of life.

Affiliation

¹Department of Child Neurology, Emma's Children's Hospital, Amsterdam University Medical Center, Vrije Universiteit, The Netherlands; ²Amsterdam Leukodystrophy Center, Amsterdam Neuroscience, Cellular & Molecular Mechanisms, The Netherlands; ³Department of Endocrinology and Metabolism, Platform "Medicine for Society", Amsterdam University Medical Center, University of Amsterdam, The Netherlands; ⁴Department of Pediatrics, Division of Pediatric Neurology, University of Utah School of Medicine, Salt Lake City; ⁵Primary Children's Hospital, Intermountain Healthcare, Salt Lake City, UT; ⁶Division of Neurology, Children's Hospital of Philadelphia, PA; ⁷Department of Neurology, Perelman School of Medicine, University of Pennsylvania, Philadelphia; ⁸Department of Developmental and Child Neurology, Social Pediatrics, University Children's Hospital Tübingen, Germany; ⁹Departments of Neurology and Neurosurgery, Pediatrics and Human Genetics, McGill University, Montreal, Quebec, Canada; ¹⁰Department Specialized Medicine, Division of Medical Genetics, McGill University Health Centre, Montreal, Quebec, Canada; ¹¹Child Health and Human Development Program, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada; ¹²Research Unit of Neuromuscular and Neurodegenerative Diseases, Ospedale Pediatrico Bambino Gesù IRCCS, Rome, Italy; ¹³Kennedy Krieger Institute, Johns Hopkins University, Baltimore, MD; ¹⁴PSEG Centro de Pesquisa Clínica, São Paulo, Brazil; ¹⁵Department of Neurology and Neurosurgery, Division of Neuromuscular Diseases, Universidade Federal de São Paulo, Brazil; ¹⁶COALA (Center for Diagnosis and Treatment of Leukodystrophies), Unit of Pediatric Neurology, V. Buzzi Children's Hospital, Milan, Italy; ¹⁷Department of Biomedical and Clinical Sciences, University of Milan, Milan, Italy; ¹⁸Reference Center for Leukodystrophies, Pediatric Neurology Department, Hôpital Bicêtre, Le Kremlin Bicêtre, France; ¹⁹Department of Neurodegenerative Diseases, Hertie-Institute for Clinical Brain Research and Center of Neurology, University of Tübingen, Germany; ²⁰German Center for Neurodegenerative Diseases (DZNE), Tübingen, Germany; ²¹Unit of Rare Neurological Diseases, Fondazione IRCCS Istituto Neurologico Carlo Besta, Milan, Italy; ²²Department of Neurology and Neurosurgery, Montreal Neurological Hospital and Institute, McGill University, Montreal, Quebec, Canada; ²³Division of General Pediatrics, Children's Hospital of Philadelphia, PA; ²⁴Department of General Pediatrics, Perelman School of Medicine, University of Pennsylvania, Philadelphia; ²⁵Department of Endocrinology and Metabolism, Amsterdam University Medical Center, The Netherlands; ²⁶Department of Pediatric Endocrinology, Amsterdam UMC location Vrije Universiteit, The Netherlands; ²⁷Amsterdam Gastroenterology Endocrinology Metabolism, The Netherlands; ²⁸Amsterdam Reproduction and Development, The Netherlands; ²⁹Department of Obstetrics & Gynecology, Division of Pediatric Gynecology, University of Utah, Salt Lake City; ³⁰Department of Pediatrics and Adolescent Medicine, RKH Klinikum Ludwigsburg, Germany; ³¹Department of Pediatric Intensive Care, Amsterdam University Medical Center, The Netherlands; ³²Division of Pediatric Endocrinology, Montreal Children's Hospital, McGill University Health Centre, Montreal, Quebec, Canada; ³³Department of Human Genetics, Amsterdam University Medical Center, The Netherlands; ³⁴Department of Pathology and Laboratory Medicine, Children's Mercy Hospital, Kansas City, MO; ³⁵Department of Pediatrics, School of Medicine, University of Missouri, Kansas City; ³⁶Genomic Medicine Center, Children's Mercy Hospital, Kansas City, MO; ³⁷Department of Nutrition and Dietetics, Internal Medicine, Amsterdam University Medical Center, The Netherlands; ³⁸United Leukodystrophy Foundation, DeKalb, IL; ³⁹VWM Families Foundation, Greenwich, CT; ⁴⁰Vereniging Volwassenen, Kinderen en Stofwisselingsziekten, Zwolle, The Netherlands; ⁴¹Biomolecular Sciences Research Centre, School of Biosciences and Chemistry, Faculty of Health, Wellbeing and Life Sciences, Sheffield Hallam University, Sheffield, United

Kingdom; ⁴²IXA Neuroscience, Amsterdam Neuroscience, Amsterdam University Medical Center, Vrije Universiteit, The Netherlands; ⁴³Department of Integrative Neurophysiology, Center for Neurogenomics and Cognitive Research, Vrije Universiteit, Amsterdam, The Netherlands.

Acknowledgment

The authors are grateful to the contributions of all physicians and specialists who provided genetic data on their patients, which facilitated the publication of the genetic variant table.

Author Contributions

R.J. van Voorst: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data. D.H. Schoenmakers: drafting/revision of the manuscript for content, including medical writing for content; major role in the acquisition of data; study concept or design; analysis or interpretation of data. J.L. Bonkowsky: drafting/revision of the manuscript for content, including medical writing for content; study concept or design. A. Vanderver: drafting/revision of the manuscript for content, including medical writing for content; study concept or design. I. Krägeloh-Mann: drafting/revision of the manuscript for content, including medical writing for content; study concept or design. G. Bernard: drafting/revision of the manuscript for content, including medical writing for content; study concept or design. E. Bertini: drafting/revision of the manuscript for content, including medical writing for content; study concept or design. A. Fatemi: drafting/revision of the manuscript for content, including medical writing for content; study concept or design. P.V. Sgobbi: drafting/revision of the manuscript for content, including medical writing for content; study concept or design. N.I. Wolf: drafting/revision of the manuscript for content, including medical writing for content; study concept or design. S. Groeschel: drafting/revision of the manuscript for content, including medical writing for content. D. Tonduti: drafting/revision of the manuscript for content, including medical writing for content. C. Sevin: drafting/revision of the manuscript for content, including medical writing for content. J.L. Orthmann-Murphy: drafting/revision of the manuscript for content, including medical writing for content. L. Schöls: drafting/revision of the manuscript for content, including medical writing for content. E. Salsano: drafting/revision of the manuscript for content, including medical writing for content. B. Brais: drafting/revision of the manuscript for content, including medical writing for content. N. Jaffe: drafting/revision of the manuscript for content, including medical writing for content. K.W. ter Horst: drafting/revision of the manuscript for content, including medical writing for content. S.E. Hannema: drafting/revision of the manuscript for content, including medical writing for content. K.G. Hayes: drafting/revision of the manuscript for content, including medical writing for content. J. Meyburg: drafting/revision of the manuscript for content, including medical writing for content. M. van Heerde: drafting/revision of the manuscript for content, including medical writing for content. A.M. Sbrocchi: drafting/revision of the manuscript for content, including medical writing for content. R. van Spaendonck:

drafting/revision of the manuscript for content, including medical writing for content. I. Thiffault: drafting/revision of the manuscript for content, including medical writing for content. G.H. Hofsteenge: drafting/revision of the manuscript for content, including medical writing for content. C. Sudmeier-Broek: drafting/revision of the manuscript for content, including medical writing for content. C. Timmer: drafting/revision of the manuscript for content, including medical writing for content. D. Skwirut: drafting/revision of the manuscript for content, including medical writing for content. A. Buck: drafting/revision of the manuscript for content, including medical writing for content. B. Hollberg: drafting/revision of the manuscript for content, including medical writing for content. R. Chapleau: drafting/revision of the manuscript for content, including medical writing for content. H. Dekker: drafting/revision of the manuscript for content, including medical writing for content. S.G. Campbell: drafting/revision of the manuscript for content, including medical writing for content; analysis or interpretation of data. T.E.M. Abbink: drafting/revision of the manuscript for content, including medical writing for content; analysis or interpretation of data. P.S. Leferink: drafting/revision of the manuscript for content, including medical writing for content. M.S. van der Knaap: drafting/revision of the manuscript for content, including medical writing for content; study concept or design.

Study Funding

This study was funded by the Dutch Research Council (NWO) through the Spinozapremie award.

Disclosure

A. Vanderver receives in-kind support from Affinia, Biogen, Calico, Boehringer Ingelheim Eli Lilly, Ionis, Myrtelle, Orchard Therapeutics, Sana Therapeutics, Sanofi, Synaptixbio, and Takeda; and serves on the boards of the European Leukodystrophy Association and the United Leukodystrophy Foundation. S. Groeschel received institutional research support from Shire plc (a Takeda company) and Orchard; and is an advisor and coinvestigator for trials in Metachromatic Leukodystrophy (Shire/Takeda, Orchard). D. Tonduti is a consultant for Orchard Therapeutics, Ionis, Egetis, and Initio Evoke; and served on the scientific advisory boards of the United Leukodystrophy Foundation. C. Sevin reports no disclosures relevant to the manuscript. J.L. Orthmann-Murphy receives or has received research funding from the National Institutes of Health, the National Multiple Sclerosis Society, the Global Leukodystrophy Initiative, the Clayco Foundation, the Simon Foundation, and ITMAT; is a site PI for Vigil Neuroscience; and is a consultant for Vigil Neuroscience and NovoGlia. S.G. Campbell is part of the Leukolabs community, a network for white matter disease research in the United Kingdom; and has received funding in the past from Great Ormond Street Hospital, GOSH Charity. T.E.M. Abbink is listed on patent P112686US00 “therapeutic effects of Guanabenz treatment in vanishing white matter” and on patent P112686CA00 “the use of Guanabenz in the

treatment of VWM,” both for the Amsterdam University Medical Center, Amsterdam, the Netherlands. P. S. Leferink reports no disclosures relevant to the manuscript. M.S. van der Knaap is coinvestigator for Ionis (Alexander disease trial) and advisor and coinvestigator for Calico and AbbVie vanishing white matter; is listed on patent P112686US00 “therapeutic effects of Guanabenz treatment in vanishing white matter” and on patent P112686CA00 “the use of Guanabenz in the treatment of VWM,” both for the Amsterdam University Medical Center, Amsterdam, the Netherlands; and is the initiator and principal investigator of the Guanabenz trial (clinicaltrialsregister.eu/ctr-search/trial/2017-001438-25/NL). Ingeborg Krägeloh-Mann, Enrico Bertini, Nicole Wolf, Samuel Groeschel, Caroline Sevin, Ludger Schöls, and Marjo van der Knaap are members of the European reference network for rare neurologic disorders (ERN-RND), project ID 739510. A. Vanderver, J. Bonkowski, A. Fatemi, J. Orthmann-Murphy, and N. Jaffe are members of the Global Leukodystrophy Initiative Clinical Trials Network (U54 NS115052). All other authors report no disclosures relevant to the manuscript. Go to Neurology.org/N for full disclosures.

Publication History

Received by *Neurology*® March 11, 2025. Accepted in final form October 6, 2025. Submitted and externally peer reviewed. The handling editors were Associate Editor Courtney Wusthoff, MD, MS, Assistant Editor Angela Vidal-Jordana, MD, PhD, and Associate Editor for Editorial Education Bradford Worrall, MD, MSc, FAAN.

References

1. van der Knaap MS, Pronk JC, Scheper GC. Vanishing white matter disease. *Lancet Neurol*. 2006;5:413-423. doi:10.1016/S1474-4422(06)70440-9
2. Hamilton EMC, van der Lei HDW, Vermeulen G, et al. Natural history of vanishing white matter. *Ann Neurol*. 2018;84(2):274-288. doi:10.1002/ana.25287
3. van der Knaap MS, Leegwater PA, Könst AA, et al. Mutations in each of the five subunits of translation initiation factor eIF2B can cause leukoencephalopathy with vanishing white matter. *Ann Neurol*. 2002;51(2):264-270. doi:10.1002/ana.10112
4. Abbink TEM, Wisse LE, Jaku E, et al. Vanishing white matter: deregulated integrated stress response as therapy target. *Ann Clin Transl Neurol*. 2019;6(8):1407-1422. doi:10.1002/acn3.50826
5. van Voorst RJ, Schoenmakers DH, van Beelen I, et al. The impact of vanishing white matter on unaffected family members. *Orphanet J Rare Dis*. 2025;20(1):456. doi:10.1186/s13023-025-03987-8
6. van der Knaap MS, Bonkowski JL, Vanderver A, et al. Therapy trial design in vanishing white matter: an expert consortium opinion. *Neurol Genet*. 2022;8(2):e657. doi:10.1212/NXG.0000000000000657
7. Schoenmakers DH, Leferink PS, Vanderver A, et al. Core protocol development for phase 2/3 clinical trials in the leukodystrophy vanishing white matter: a consensus statement by the VWM consortium and patient advocates. *BMC Neurol*. 2023;23(1):305. doi:10.1186/s12883-023-03354-9
8. vwmconsortium.org
9. Burns PB, Rohrich RJ, Chung KC. The levels of evidence and their role in evidence-based medicine. *Plast Reconstr Surg*. 2011;128(1):305-310. doi:10.1097/PRS.0b013e318219c171
10. Accessed April 1, 2024. edelphi.org/
11. Diamond IR, Grant RC, Feldman BM, et al. Defining consensus: a systematic review recommends methodologic criteria for reporting of Delphi studies. *J Clin Epidemiol*. 2014;67(4):401-409. doi:10.1016/j.jclinepi.2013.12.002
12. van der Knaap MS, Bugiani M, Boor I, Proud CG, Scheper GC. Vanishing white matter. In: Valle DL, Antonarakis S, Ballabio A, Beaudet AL, Mitchell GA, eds. *The Online Metabolic and Molecular Bases of Inherited Disease*. McGraw-Hill Education; 2010.
13. Accessed September 1, 2024. franklin.genoox.com
14. Stellingwerf MD, Al-Saady ML, van de Brug T, Barkhof F, Pouwels PJW, van der Knaap MS. MRI natural history of the leukodystrophy vanishing white matter. *Radiology*. 2021;300(3):671-680. doi:10.1148/radiol.2021210110
15. Stellingwerf MD, van de Wiel MA, van der Knaap MS. Radiological correlates of episodes of acute decline in the leukodystrophy vanishing white matter. *Neuroradiology*. 2023;65(4):855-863. doi:10.1007/s00234-022-03097-3
16. Roosendaal SD, van de Brug T, Alves C, et al. Imaging patterns characterizing mitochondrial leukodystrophies. *AJNR Am J Neuroradiol*. 2021;42(7):1334-1340. doi:10.3174/ajnr.A7097

17. van der Lei HD, van Berkel CG, van Wieringen WN, et al. Genotype-phenotype correlation in vanishing white matter disease. *Neurology*. 2010;75(17):1555-1559. doi: 10.1212/WNL.0b013e3181f962ae
18. Slynko I, Nguyen S, Hamilton EMC, et al. Vanishing white matter: eukaryotic initiation factor 2B model and the impact of missense mutations. *Mol Genet Genomic Med*. 2021;9(3):e1593. doi:10.1002/mgg3.1593
19. Pakos-Zebrucka K, Koryga I, Mnich K, Ljujic M, Samali A, Gorman AM. The integrated stress response. *EMBO Rep*. 2016;17(10):1374-1395. doi:10.15252/embr.201642195
20. Wek RC, Anthony TG, Staschke KA. Surviving and adapting to stress: translational control and the integrated stress response. *Antioxid Redox Signal*. 2023;39(4-6):351-373. doi:10.1089/ars.2022.0123
21. Sihra N, Goodman A, Zakri R, Sahai A, Malde S. Nonantibiotic prevention and management of recurrent urinary tract infection. *Nat Rev Urol*. 2018;15(12):750-776. doi:10.1038/s41585-018-0106-x
22. Bugiani M, Postma N, Polder E, et al. Hyaluronan accumulation and arrested oligodendrocyte progenitor maturation in vanishing white matter disease. *Brain*. 2013;136(pt 1):209-222. doi:10.1093/brain/aws320
23. Jurkiewicz E, Mierzewska H, Bekiesińska-Figatowska M, et al. MRI of a family with leukoencephalopathy with vanishing white matter. *Pediatr Radiol*. 2005;35(10):1027-1030. doi:10.1007/s00247-005-1498-3
24. Sijens PE, Boon M, Meiners LC, Brouwer OF, Oudkerk M. 1H chemical shift imaging, MRI, and diffusion-weighted imaging in vanishing white matter disease. *Eur Radiol*. 2005;15(11):2377-2379. doi:10.1007/s00330-005-2783-0
25. Karimi R, Cleven A, Elbarbry F, Hoang H. The impact of fasting on major metabolic pathways of macronutrients and pharmacokinetics steps of drugs. *Eur J Drug Metab Pharmacokinet*. 2021;46(1):25-39. doi:10.1007/s13318-020-00656-y
26. Felig P, Owen OE, Wahren J, Cahill GF Jr. Amino acid metabolism during prolonged starvation. *J Clin Invest*. 1969;48(3):584-594. doi:10.1172/JCI106017
27. Hommel S, Lücke T, Schmidt-Choudhury A. Nutritional management in children and adolescents with severe neurological impairment-who cares? A web-based survey among pediatric specialists in Germany. *Neuropediatrics*. 2023;54(6):371-380. doi: 10.1055/s-0043-1772708
28. Burgos R, Bretón I, Cereda E, et al. ESPEN guideline clinical nutrition in neurology. *Clin Nutr*. 2018;37(1):354-396. doi:10.1016/j.clnu.2017.09.003
29. Romano C, van Wynckel M, Hulst J, et al. European Society for Paediatric Gastroenterology, Hepatology and Nutrition guidelines for the evaluation and treatment of gastrointestinal and nutritional complications in children with neurological impairment. *J Pediatr Gastroenterol Nutr*. 2017;65(2):242-264. doi:10.1097/MPG.0000000000001646
30. Edouard T, Guillaume-Czitrom S, Bacchetta J, et al. Guidelines for the management of children at risk of secondary bone fragility: expert opinion of a French working group. *Arch Pediatr*. 2020;27(7):393-398. doi:10.1016/j.arcped.2020.07.008
31. NIH Consensus Development Panel on Osteoporosis Prevention, Diagnosis, and Therapy. Osteoporosis prevention, diagnosis, and therapy. *JAMA*. 2001;285(6):785-795. doi:10.1001/jama.285.6.785
32. Behboudi-Gandevani S, Arntzen EC, Normann B, Haugan T, Bidhendi-Yarandi R. Cardiovascular events among women with premature ovarian insufficiency: a systematic review and meta-analysis. *Rev Cardiovasc Med*. 2023;24(7):193. doi: 10.31083/j.rcm.2407193
33. La Piana R, Vanderver A, van der Knaap M, et al. Adult-onset vanishing white matter disease due to a novel EIF2B3 mutation. *Arch Neurol*. 2012;69(6):765-768. doi: 10.1001/archneurol.2011.1942
34. Robinson M, Rossignol E, Brais B, Rouleau G, Arbour JF, Bernard G. Vanishing white matter disease in French-Canadian patients from Quebec. *Pediatr Neurol*. 2014;51(2):225-232. doi:10.1016/j.pediatrneurol.2014.05.006
35. Peter L, Niel F, Catenioix H, et al. Acute neurological deterioration in ovarioleukodystrophy related to EIF2B mutations: pregnancy with oocyte donation is a potentially precipitating factor. *Eur J Neurol*. 2008;15(1):94-97. doi:10.1111/j.1468-1331.2007.01999.x
36. Schoenmakers DH, van Beelen I, Voermans MMC, et al. Adaptive behavior assessed by Vineland-3 as comprehensive outcome measure in vanishing white matter. *Ann Clin Transl Neurol*. 2024;11(3):650-661. doi:10.1002/acn3.51985
37. Smith NR, Bally JMG, Holtslander L, et al. Supporting parental caregivers of children living with life-threatening or life-limiting illnesses: a Delphi study. *J Spec Pediatr Nurs*. 2018;23(4):e12226. doi:10.1111/jspn.12226
38. Dooves S, Bugiani M, Postma NL, et al. Astrocytes are central in the pathomechanisms of vanishing white matter. *J Clin Invest*. 2016;126(4):1512-1524. doi:10.1172/JCI83908
39. Wisse LE, ter Braak TJ, van de Beek M-C, et al. Adult mouse eIF2Bε Arg191His astrocytes display a normal integrated stress response in vitro. *Sci Rep*. 2018;8(1):3773. doi:10.1038/s41598-018-21885-x
40. Wisse LE, Visser D, ter Braak TJ, et al. Isocaloric low protein diet in a mouse model for vanishing white matter does not impact ISR deregulation in brain, but reveals ISR deregulation in liver. *Nutr Neurosci*. 2022;25(6):1219-1230. doi:10.1080/1028415X.2020.1846356
41. Engelen M, van Ballegoij WJC, Mallack EJ, et al. International recommendations for the diagnosis and management of patients with adrenoleukodystrophy: a consensus-based approach. *Neurology*. 2022;99(21):940-951. doi:10.1212/WNL.000000000000201374
42. Adang LA, Bonkowski JL, Boelens JJ, et al. Consensus guidelines for the monitoring and management of metachromatic leukodystrophy in the United States. *Cytotherapy*. 2024;26(7):739-748. doi:10.1016/j.jcyt.2024.03.487
43. Hohmann E, Cote MP, Brand JC. Research pearls: expert consensus based evidence using the Delphi method. *Arthroscopy*. 2018;34(12):3278-3282. doi:10.1016/j.arthro.2018.10.004

eFigure 1. Search string and flow diagram of the literature review for evidence statements diagnosis and management of VWM


((((((((((((((Vanishing White Matter[Title/Abstract]) OR (VWM[Title/Abstract])) OR (Childhood ataxia with central hypomyelination[Title/Abstract])) OR (CACH[Title/Abstract])) OR (Childhood ataxia with central nervous system hypomyelination[Title/Abstract])) OR (Childhood Ataxia with Diffuse Central Nervous System Hypomyelination[Title/Abstract])) OR (Vanishing White Matter Leukodystrophy[Title/Abstract])) OR (Vanishing White Matter Leukodystrophy with Ovarian Failure[Title/Abstract])) OR (Leukoencephalopathy with Vanishing White Matter[Title/Abstract])) OR (Vanishing White Matter Disease[Title/Abstract])) OR (CACH VWM Syndrome[Title/Abstract])) OR (Eukaryotic initiation factor 2B related dis[Title/Abstract])) OR (Eukaryotic initiation factor 2B-related dis*[Title/Abstract])) OR (eIF2B-related dis*[Title/Abstract])) OR (eIF2B related dis*[Title/Abstract])) OR (eIF2B-related leukodystroph*[Title/Abstract])) OR (eIF2B related leukodystroph*[Title/Abstract])) OR (Ovarioleukodystrophy[Title/Abstract]) **NOT** (visual working memory[Title/Abstract]) **NOT** (verbal working memory[Title/Abstract]))*

Date search performed: 10-November-2023

Filters applied: Humans, Dutch, English.

Period: 2000 – 2023

Hits: 319




eFigure 2. Search string (#01-#11) and flow diagram of the literature review for clinically used drugs investigated for ISR effects

Search string:

#01("activating transcription factor 4/genetics"[MeSH Terms] OR "activating transcription factor 4/metabolism"[MeSH Terms] OR ("transcription factor chop"[MeSH Terms] OR ("Transcription"[All Fields] AND "Factor"[All Fields] AND "CHOP"[All Fields]) OR "transcription factor chop"[All Fields]) AND "metabolism*"[MeSH Terms]) OR "transcription factor chop/genetics"[MeSH Terms] OR ("eukaryotic initiation factor 2"[MeSH Terms] OR ("Eukaryotic"[All Fields] AND "Initiation"[All Fields] AND "factor 2"[All Fields]) OR "eukaryotic initiation factor 2"[All Fields] OR "eukaryotic initiation factor 2"[All Fields]) AND "genetics"[MeSH Terms]) OR ("eukaryotic initiation factor 2"[MeSH Terms] OR ("Eukaryotic"[All Fields] AND "Initiation"[All Fields] AND "factor 2"[All Fields]) OR "eukaryotic initiation factor 2"[All Fields] OR "eukaryotic initiation factor 2"[All Fields]) AND "metabolism*"[MeSH Terms]) OR ("eif 2 kinase"[MeSH Terms] OR ("eif 2"[All Fields] AND "kinase"[All Fields]) OR "eif 2 kinase"[All Fields] OR "eif 2 kinase"[All Fields]) AND "metabolism*"[MeSH Terms]) OR ("eif 2 kinase"[MeSH Terms] OR ("eif 2"[All Fields] AND "kinase"[All Fields]) OR "eif 2 kinase"[All Fields] OR "eif 2 kinase"[All Fields]) AND "genetics*"[MeSH Terms]) OR "eukaryotic initiation factors/genetics"[MeSH Terms] OR ("eukaryotic initiation factors"[MeSH Terms] OR ("Eukaryotic"[All Fields] AND "Initiation"[All Fields] AND "Factors"[All Fields]) OR "eukaryotic initiation factors"[All Fields]) AND "metabolism*"[MeSH Terms]) OR "eukaryotic initiation factor 2"[MeSH Terms] OR "eukaryotic initiation factors*"[MeSH Terms] OR "integrated stress response"[Title/Abstract] OR "ISR"[Title/Abstract] OR "ATF4"[Title/Abstract] OR "CHOP"[Title/Abstract] OR "DDIT3"[Title/Abstract] OR ("dna damage"[MeSH Terms] OR ("dna"[All Fields] AND "damage"[All Fields]) OR "dna damage"[All Fields]) AND "induced transcript 3"[Title/Abstract]) OR "EIF2"[Title/Abstract]) AND **#02** ("tranquilizing agents/therapy"[MeSH Terms] OR "hypnotics and sedatives/therapeutic use"[MeSH Terms] OR "Sedatives"[Title/Abstract] OR **#03** ("anticonvulsants/therapeutic use"[MeSH Terms] OR "anticonvulsants/pharmacology"[MeSH Terms] OR "epilepsy/drug therapy"[MeSH Terms]) OR "benzodiazepines/therapeutic use"[MeSH Terms] OR **#04** ("adrenal cortex hormones/therapeutic use"[MeSH Terms] OR "glucocorticoids/therapeutic use"[MeSH Terms] OR "Corticosteroids"[Title/Abstract]) OR **#05** ("antidepressive agents/therapeutic use"[MeSH Terms] OR "selective serotonin reuptake inhibitors/therapeutic use"[MeSH Terms] OR "depressive disorder/drug therapy"[MeSH Terms] OR "antidepressive agents, tricyclic/therapeutic use"[MeSH Terms] OR "depressive disorder/drug therapy"[MeSH Terms] OR "depressive disorder, major/drug therapy"[MeSH Terms] OR "antipsychotic agents/therapeutic use"[MeSH Terms] OR "schizophrenia/drug therapy"[MeSH Terms] OR "mental disorders/drug therapy"[MeSH Terms] OR "psychotic disorders/drug therapy"[MeSH Terms]) OR **#06** ("antiviral agents/therapeutic use"[MeSH Terms] OR ("anti bacterial agents"[Pharmacological Action] OR "anti bacterial agents"[MeSH Terms] OR ("anti bacterial"[All Fields] AND "Agents"[All Fields]) OR "anti bacterial agents"[All Fields] OR ("anti"[All Fields] AND "bacterial"[All Fields] AND "Agents"[All Fields]) OR "anti bacterial agents"[All Fields]) AND "therapeutic uses"[MeSH Terms])) OR **#07** ("analgesics, opioid/therapeutic use"[MeSH Terms] OR "chronic pain/drug therapy"[MeSH Terms] OR "receptors, opioid/drug effects"[MeSH Terms]) OR **#08** ("angiotensin ii type 1 receptor blockers/therapeutic use"[MeSH Terms] OR "hypertension/drug therapy"[MeSH Terms] OR "antihypertensive agents/therapeutic use"[MeSH Terms] OR ("adrenergic beta antagonists"[Pharmacological Action] OR "adrenergic beta antagonists"[MeSH Terms] OR ("adrenergic"[All Fields] AND "beta antagonists"[All Fields]) OR "adrenergic beta antagonists"[All Fields] OR ("adrenergic"[All Fields] AND "beta"[All Fields] AND "antagonists"[All Fields]) OR "adrenergic beta antagonists"[All Fields]) AND "therapeutic uses"[MeSH Terms])) OR **#09** ("immunosuppressive drugs"[Title/Abstract] OR "anti inflammatory drugs"[Title/Abstract] OR "nonsteroidal anti inflammatory drugs"[Title/Abstract] OR "NSAIDs"[Title/Abstract] OR "antipyretics"[Title/Abstract] OR "antipyretics/therapeutic use"[MeSH Terms]) OR **#10** ("anesthetics"[MeSH Terms] OR "anesthetics, inhalation"[MeSH Terms] OR "anesthesia, general"[MeSH Terms] OR "anesthetics, intravenous"[MeSH Terms])) OR **#11** "Spasmolytica"[Title/Abstract]

- Date search performed: 5-April-2024
- Filters applied: Humans, Dutch, English.
- Period: 2000 – 2024
- Hits 738



eFigure 3. Patient management card, front side (A) and back side (B).

Vanishing White Matter

Patient Management Card

Recommendations for preventive measures and acute care settings

Introduction

- Vanishing White Matter is a rare genetic disease leading to progressive motor and cognitive dysfunction.
- Episodes of acute decline may occur. These episodes can be triggered by physical stressors, like fever, infections, head trauma and certain anesthetics.
- There is no cure for VWM, but there are best practices for clinical management.
- This leaflet contains key recommendations for preventive measures and acute care settings.

Do's

- Use ibuprofen in the case of fever, add paracetamol/acetaminophen if necessary
- Use antibiotics in the case of a (suspected) bacterial infection
- Propofol is preferred if anesthesia is needed
- Treat epilepsy
- Follow the regular vaccination program, including Influenza and COVID-19 vaccinations
- Wear a helmet for activities with a risk of head trauma
- Apply standard behavioral management

Don'ts

- Contact sports
- Inhalation anesthetics

Recommendations for patients



Measures to prevent episodes of acute decline

- In the case of fever, use paracetamol/acetaminophen, ibuprofen or both to normalize body temperature.
 - In case of febrile infection, check with your physician if antibiotics are needed.
- Follow the regular national vaccination program, including yearly Influenza vaccine and up-to-date vaccination against COVID-19, and give ibuprofen to avoid fever.
- Wear a helmet for activities associated with enhanced risk of head trauma, such as bicycling.
- Avoid contact sports.
- Major surgical procedures carry extra risks for patients with VWM and benefits should therefore be carefully weighed before proceeding.
- Standard behavioral management is safe, as psychological stress is not linked to acute decline.

© 2025 – VWM consortium - Version 1

Recommendations for physicians

Measures to prevent episodes of acute decline

- We recommend balancing the need for major surgical procedures against the risk of anesthesia and physical stress related to the procedure. PEG tube placement is a minor surgery. Other advices around surgical procedures are provided in the scientific publication mentioned in Read More.
- We suggest close monitoring after head trauma, surgical procedures and use of anesthetics.
- In the case of previous acute severe decline, we recommend to consider hospital admission with intensive care possibility when a similar stressor occurs.
- Consider avoiding drugs that activate the integrated stress response, especially inhalation anesthetics like sevoflurane. Use propofol instead.
- We recommend to start ibuprofen in the case of fever or vaccinations, aiming at normal temperature. Add paracetamol/acetaminophen if necessary.
- We recommend to maintain a good nutritional status.

Acute presentation management

- We recommend prompt investigations in the case of fever, with a low threshold for empiric antibiotics, if a bacterial cause is suspected.
- We recommend to consider hospital admission with intensive care availability in the case of acute neurological decline.
- A short course of corticosteroids can be considered in the case of acute severe neurological decline (e.g. with reduced level of consciousness, loss of walking), if there are no contraindications.



Questions? Please contact:
vwmconsortium@amsterdamumc.nl

Read more

The complete scientific article with all recommendations on diagnosis and management of VWM was published open-access (DOI: tba)

About us

This leaflet was established by VWM experts from the VWM consortium and patient advocates from the United Leukodystrophy Foundation (ULF), European Leukodystrophy Association (ELA), and Volwassenen, Kinderen en Stofwisselingsziekten (VKS).

Disclaimer

The information in this leaflet is carefully established based on scientific evidence and expert opinions. Future developments may lead to changes in these recommendations. Please check whether an updated version is available on <https://www.VWMconsortium.org/about-vwm/>

eTable 1. Overview of requested voting per recommendation topic by panelists.

Topic	VWM consortium (n=9)	Leukodystrophy experts (n=7)	Endocrinologist (n=3)	Complex Care pediatrician (n=1)	Geneticists (n=2)	Pediatric intensivists (n=2)	Pediatric gynecologist (n=1)	Total expected votes (n)
Diagnosis	x	x			x			18
Prediction of disease course	x	x						16
Preventive measures episode	x	x	x	x				20
Medication	x	x	x	x				20
Acute presentation management	x	x	x	x		x		22
Chronic disease management-nutrition	X	x	x	x				20
Chronic disease management-epilepsy	X	x	x	x				20
Chronic disease management- ovarian insufficiency and bone health	X	x	x	x			x	21
Chronic disease management-pregnancy and delivery	X	x	x	x			x	21

eTable 2. Grading scheme for the level of evidence modified from Burns et al., 2012

Level 1	High quality prospective cohort study with adequate power or systematic review of these studies
Level 2	Lesser quality prospective cohort, retrospective cohort study, untreated controls from an RCT, or systematic review of these studies
Level 3	Case-control study or systematic review of these studies
Level 4	Case series (n<10 patients) or literature review
Level 5	Expert opinion, case report or clinical example, or evidence based on physiology, bench research or “first principles”

eTable 3. Consensus-based recommendations, strength and evidence

Number	Strength	Recommendation	Agreement (%)
Diagnosis (avoiding false negative and false positive diagnoses)			
1.1	A	Genetic confirmation should always be sought after suspected VWM diagnosis based on brain MRI findings. Stellingwerff et al., 2021 ^{e1} (level 2); Stellingwerff et al., 2023 ^{e2} (level 2); Fogli et al., 2004 ^{e3} (level 2); Aygnac et al., 2015 ^{e4} (level 2); Van der Lei et al., 2012 ^{e5} (level 4); Mahdiah et al., 2021 ^{e6} (level 4)	100%
1.2	B	If a brain MRI is consistent with VWM (see description), the diagnosis of VWM is confirmed by the presence of two pathogenic or likely pathogenic variants or variants of unknown significance in one of the <i>EIF2B1-5</i> genes. Slynko et al., 2021 ^{e7} (level 2); Fogli et al., 2004 ^{e3} (level 2); Leegwater et al., 2001 ^{e8} (level 2); Van der Knaap et al., 2002 ^{e9} (level 4)	100%
1.3	A	If a brain MRI is consistent with VWM (see description) and a single pathogenic or likely pathogenic variant or variant of unknown significance is found in one of the <i>EIF2B1-5</i> genes, we recommend extra efforts to identify a second variant in the same gene. Slynko et al., 2021 ^{e7} (level 2); Fogli et al., 2004 ^{e3} (level 2); Leegwater et al., 2001 ^{e8} (level 2); Van der Knaap et al., 2002 ^{e9} (level 3)	100%
1.4	A	If a brain MRI is consistent with VWM and no (likely) pathogenic variants or variants of unknown significance in one of the <i>EIF2B1-5</i> genes can be found, we recommend searching for another cause. Aygnac et al., 2015 ^{e4} (level 2); Labauge et al., 2009 ^{e10} (level 4); Köhler et al., 2018 ^{e11} (level 4); Patay et al., 2005 ^{e12} (level 4); Mahdiah et al., 2021 ^{e6} (level 4); Khorrami et al., 2021 ^{e13} (level 5); Tian et al., 2022 ^{e14} (level 5); Deginet et al., 2021 ^{e15} (level 5)	100%
1.5	A	If variants in one of the <i>EIF2B1-5</i> genes are found in a patient, we recommend evaluation of a recent brain MRI to help determine a diagnosis of VWM. Stellingwerff et al., 2021 ^{e1} (level 2); Stellingwerff et al., 2023 ^{e2} (level 2); Fogli et al., 2004 ^{e3} (level 2); Van der Lei et al., 2012 ^{e5} (level 4)	100%
1.6	A	When an index patient is diagnosed, we recommend genetic counseling to discuss family screening and family planning. Slynko et al., 2021 ^{e7} (level 2); Leegwater et al., 2001 ^{e8} (level 2); Pronk et al., 2006 ^{e16} (level 4); Van der Knaap et al., 2003 ^{e17} (level 4)	100%
Prediction of disease course			
2.1	A	Disease course can be predicted for age of onset < 4 years based on age of first signs, except for developmental delay. Hamilton et al., 2018 ^{e18} (level 2); Fogli et al., 2004 ^{e3} (level 2); Güngör et al., 2020 ^{e19} (level 2); Zhang et al., 2015 ^{e20} (level 2); Shimada et al., 2015 ^{e21} (level 2); Van der Knaap et al., 2003 ^{e22} (level 4)	100%
2.2	A	Known gene variants can help predict the disease course. Slynko et al., 2021 ^{e7} (level 2); Van der lei et al., 2010 ^{e23} (level 2); Güngör et al., 2020 ^{e19} (level 2); Labauge et al., 2009 ^{e24} (level 2); Fogli et al., 2004 ^{e3} (level 2); Zhang et al., 2015 ^{e20} (level 2); Shimada et al., 2015 ^{e21} (level 2)	100%
2.3	A	Episodes of acute decline predict a worse disease course. Hamilton et al., 2018 ^{e18} (level 2); Güngör et al., 2020 ^{e19} (level 2); Labauge et al., 2009 ^{e24} (level 2); Fogli et al., 2004 ^{e3} (level 2); Wu et al., 2009 ^{e25} (level 2); Zhang et al., 2015 ^{e20} (level 2); Shimada et al., 2015 ^{e21} (level 2); Zhou et al., 2018 ^{e26} (level 2); Ren et al., 2022 ^{e27} (level 2)	100%
2.4	A	Seizures predict a worse disease course. Hamilton et al., 2018 ^{e18} (level 2); Güngör et al., 2020 ^{e19} (level 2); Labauge et al., 2009 ^{e24} (level 2); Zhou et al., 2018 ^{e26} (level 2); Ren et al., 2022 ^{e27} (level 2)	100%

2.5		We suggest counselling families on predicted disease course based on the following statements:	
2.5.1	A	A lower age at symptom onset is associated with a faster and more severe deterioration. Hamilton et al., 2018 ^{e18} (level 2); Fogli et al., 2004 ^{e3} (level 2); Güngör et al., 2020 ^{e19} (level 2); Zhang et al., 2015 ^{e20} (level 2); Shimada et al., 2015 ^{e21} (level 2); Van der Knaap et al., 2003 ^{e22} (level 4)	100%
2.5.2	B	Genotype is predictive of the phenotype. Slynko et al., 2021 ^{e7} (level 2); Van der lei et al., 2010 ^{e23} (level 2); Güngör et al., 2020 ^{e19} (level 2); Labauge et al., 2009 ^{e24} (level 2); Fogli et al., 2004 ^{e3} (level 2); Zhang et al., 2015 ^{e20} (level 2); Shimada et al., 2015 ^{e21} (level 2)	100%
2.5.3	A	Factors known to precipitate episodes of rapid decline should be avoided because such episodes are associated with a more severe disease course. Hamilton et al., 2018 ^{e18} (level 2); Güngör et al., 2020 ^{e19} (level 2); Labauge et al., 2009 ^{e24} (level 2); Fogli et al., 2004 ^{e3} (level 2); Wu et al., 2009 ^{e25} (level 2); Zhang et al., 2015 ^{e20} (level 2); Shimada et al., 2015 ^{e21} (level 2); Zhou et al., 2018 ^{e26} (level 2); Ren et al., 2022 ^{e27} (level 2)	100%
2.5.4	A	Treatment of epilepsy and seizures is important because patients with seizures have a more severe disease course. Hamilton et al., 2018 ^{e18} (level 2); Güngör et al., 2020 ^{e19} (level 2); Labauge et al., 2009 ^{e24} (level 2); Zhou et al., 2018 ^{e26} (level 2); Ren et al., 2022 ^{e27} (level 2)	100%
Measures to prevent episodes of rapid decline			
3.1	A	In the case of fever, we recommend the prompt use of antipyretics aiming at normal temperature. Leegwater et al., 2001 ^{e8} (level 2); Van der Knaap et al., 2003 ^{e17} (level 4); Van der Knaap et al., 2006 ^{e28} (level 4); Pronk et al., 2006 ^{e16} (level 4) Pakos-Zebrucka et al., 2016 ^{e29} (level 5); Wek et al., 2023 ^{e30} (level 5)	94%
3.2	A	In the case of a febrile infection, we recommend close follow-up and to consider early use of antibiotics. Leegwater et al., 2001 ^{e8} (level 2); Van der Knaap et al., 2003 ^{e17} (level 4); Van der Knaap et al., 2006 ^{e28} (level 4); Pronk et al., 2006 ^{e16} (level 4) Pakos-Zebrucka et al., 2016 ^{e29} (level 5); Wek et al., 2023 ^{e30} (level 5)	100%
3.3	B	In the case of recurrent and documented bacterial infections, prophylactic antibiotics can be considered in consultation with infectious diseases and/or immunology. Leegwater et al., 2001 ^{e8} (level 2); Van der Knaap et al., 2003 ^{e17} (level 4); Van der Knaap et al., 2006 ^{e28} (level 4); Pronk et al., 2006 ^{e16} (level 4) Pakos-Zebrucka et al., 2016 ^{e29} (level 5); Wek et al., 2023 ^{e30} (level 5)	100%
3.4	B	We recommend vaccination according to the regular national vaccination program, provided that antipyretics are given to avoid fever as much as possible. Hamilton et al., 2018 ^{e18} (level 2); Leegwater et al., 2001 ^{e8} (level 2); Van der Knaap et al., 2003 ^{e17} (level 4); Van der Knaap et al., 2006 ^{e28} (level 4); Pronk et al., 2006 ^{e16} (level 4) Pakos-Zebrucka et al., 2016 ^{e29} (level 5); Wek et al., 2023 ^{e30} (level 5)	100%
3.5	A	We specifically recommend vaccination against frequent infections, such as influenza and COVID-19. Hamilton et al., 2018 ^{e18} (level 2); Leegwater et al., 2001 ^{e8} (level 2); Van der Knaap et al., 2003 ^{e17} (level 4); Van der Knaap et al., 2006 ^{e28} (level 4); Pronk et al., 2006 ^{e16} (level 4) Pakos-Zebrucka et al., 2016 ^{e29} (level 5); Wek et al., 2023 ^{e30} (level 5)	100%
3.6	A	We recommend wearing a helmet for daily-life activities associated with enhanced risk of head trauma, such as bicycling. Hamilton et al., 2018 ^{e18} (level 2); Labauge et al., 2009 ^{e24} (level 2); Shimada et al., 2015 ^{e21} (level 2); Van der Knaap et al., 2006 ^{e28} (level 4); Pakos-Zebrucka et al., 2016 ^{e29} (level 5); Wek et al., 2023 ^{e30} (level 5); Vinogradsky et al., 2021 ^{e31} (level 5)	100%
3.7	B	We recommend avoiding sports activities associated with enhanced risk of head trauma.	100%

		Hamilton et al., 2018 ^{e18} (level 2); Labauge et al., 2009 ^{e24} (level 2); Shimada et al., 2015 ^{e21} (level 2); Van der Knaap et al., 2006 ^{e28} (level 4); Pakos-Zebrucka et al., 2016 ^{e29} (level 5); Wek et al., 2023 ^{e30} (level 5); Vinogradsky et al., 2021 ^{e31} (level 5)	
3.8	A	We recommend balancing the need for major surgical procedures against the risk of anesthesia and physical stress related to the procedure. PEG tube placement is a minor surgery. Hamilton et al., 2018 ^{e18} (level 2); Van der Knaap et al., 2003 ^{e17} (level 4); Van der Knaap et al., 2006 ^{e28} (level 4); Valalik et al., 2012 ^{e32} (level 5)	100%
3.9	A	In general, consideration should be given to non-surgical alternatives for major surgery. Van der Knaap et al., 2006 ^{e28} (level 4); Van der Knaap et al., 2003 ^{e17} (level 4)	100%
3.10	A	In general, consideration should be given to alternatives for the implantation of a foreign body enhancing the risk of infection. Van der Knaap et al., 2006 ^{e28} (level 4); Van der Knaap et al., 2003 ^{e17} (level 4)	100%
3.11	A	We recommend discussing infection prevention and close monitoring with the surgical and anesthesiology team before surgical procedures. Van der Knaap et al., 2006 ^{e28} (level 4); Van der Knaap et al., 2003 ^{e17} (level 4)	100%
3.12	B	We recommend avoiding catabolism. Hommel et al., 2023 ^{e33} (level 5)	100%
3.13	A	We suggest close monitoring after head trauma, surgical procedures and the use of anesthetics. Hamilton et al., 2018 ^{e18} (level 2); Van der Knaap et al., 2006 ^{e28} (level 4); Valalik et al., 2012 ^{e32} (level 5)	100%
3.14	A	In the case of previous acute severe decline, we recommend considering hospital admission with high care possibility when a similar stressor occurs. Hamilton et al., 2018 ^{e18} (level 2); Van der Knaap et al., 2006 ^{e28} (level 4); Valalik et al., 2012 ^{e32} (level 5)	100%
3.15	B	Apart from acute severe fright, psychological stress is not known to provoke acute decline; we therefore recommend standard behavioral management. Van der Knaap et al., 2006 ^{e28} (level 4); Kaczorowska et al., 2006 ^{e34} (level 5); Vermeulen et al., 2005 ^{e35} (level 5)	100%
Medication			
4.1	B	We recommend avoiding drugs that activate the integrated stress response, because they may trigger rapid decline. Hamilton et al., 2018 ^{e18} (level 2); Van der Knaap et al., 2006 ^{e28} (level 4); eTable 7 references	88%
4.2	A	If the drug of choice may activate the integrated stress response and there is no good alternative, the risk of the drug should be weighed against the risk or impact of the problem, which instigated the drug. Hamilton et al., 2018 ^{e18} (level 2); Van der Knaap et al., 2006 ^{e28} (level 4); eTable 7 references	100%
Acute presentation management			
5.1	A	We recommend to start with antipyretics in the case of fever aiming at normal temperature. Leegwater et al., 2001 ^{e8} (level 2); Van der Knaap et al., 2003 ^{e17} (level 4); Van der Knaap et al., 2006 ^{e28} (level 4); Pronk et al., 2006 ^{e16} (level 4) Pakos-Zebrucka et al., 2016 ^{e29} (level 5); Wek et al., 2023 ^{e30} (level 5)	95%
5.2	A	We recommend to consider treatment with antibiotics in the case of fever. Leegwater et al., 2001 ^{e8} (level 2); Van der Knaap et al., 2003 ^{e17} (level 4); Van der Knaap et al., 2006 ^{e28} (level 4); Pronk et al., 2006 ^{e16} (level 4) Pakos-Zebrucka et al., 2016 ^{e29} (level 5); Wek et al., 2023 ^{e30} (level 5)	89%
5.3	A	We recommend to consider hospital admission with high care possibility in the case of acute neurological decline. Van der Knaap et al., 2006 ^{e28} (level 4)	100%

5.4	C	We recommend considering to start with corticosteroids in the case of acute severe neurological decline (e.g., reduced level of consciousness, loss of ability to walk), if there is no contra-indication. Sjiens et al., 2005 ^{e36} (level 5); Jurkiewicz et al., 2005 ^{e37} (level 5); Mathis et al., 2008 ^{e38} (level 5); Bugiani et al., 2013 ^{e39} (level 5)	100%
Chronic disease management – Epilepsy			
6.1.1	A	We recommend to start maintenance anticonvulsant treatment in the case of a (likely) seizure, even after a single event. Hamilton et al., 2018 ^{e18} (level 2); Güngör et al., 2020 ^{e19} (level 2); Labauge et al., 2009 ^{e24} (level 2); Ren et al., 2022 ^{e27} (level 2); Zhou et al., 2018 ^{e26} (level 2) Van der Knaap et al., 2003 ^{e17} (level 4);	83.33%
Chronic disease management – Nutrition			
6.2.1	A	We recommend to maintain a good nutritional status and use (PEG) tube feeding when sufficient oral intake cannot be guaranteed. Hommel et al., 2023 ^{e33} (level 5)	100%
Chronic disease management – Ovarian insufficiency and bone health			
6.3.1	A	As ovarian insufficiency is a common feature in female patients with VWM, we recommend referral to an endocrinologist in the case of primary amenorrhea at the age of 15 or secondary amenorrhea at any age. Hamilton et al., 2018 ^{e18} (level 2); Ren et al., 2022 ^{e27} (level 2); Fogli et al., 2006 ^{e40} (level 4); Van der Knaap et al., 2003 ^{e17} (level 4); Wei et al., 2019 ^{e41} (level 4); Mathis et al., 2008 ^{e38} (level 4); Fogli et al., 2003 ^{e42} (level 4); Ibitoye et al., 2016 ^{e43} (level 5)	100%
6.3.2	A	We recommend to counsel female patients about the consequences of estrogen deficiency in terms of fertility, osteoporosis and sexual health. Hamilton et al., 2018 ^{e18} (level 2); Ren et al., 2022 ^{e27} (level 2); Fogli et al., 2006 ^{e40} (level 4); Van der Knaap et al., 2003 ^{e17} (level 4); Wei et al., 2019 ^{e41} (level 4); Mathis et al., 2008 ^{e38} (level 4); Fogli et al., 2003 ^{e42} (level 4); Ibitoye et al., 2016 ^{e43} (level 5)	100%
6.3.3	A	We recommend to monitor risk factors for osteoporosis and refer to an endocrinologist when present. Hamilton et al., 2018 ^{e18} (level 2); Ren et al., 2022 ^{e27} (level 2); Fogli et al., 2006 ^{e40} (level 4); Van der Knaap et al., 2003 ^{e17} (level 4); Wei et al., 2019 ^{e41} (level 4); Mathis et al., 2008 ^{e38} (level 4); Fogli et al., 2003 ^{e42} (level 4); Ibitoye et al., 2016 ^{e43} (level 5)	100%
Chronic disease management – Pregnancy and delivery			
6.4.1	A	We recommend close monitoring of female patients with VWM during pregnancy. Robinson et al., 2014 ^{e44} (level 4); Peter et al., 2008 ^{e45} (level 5); La Piana et al., 2012 ^{e46} (level 5)	100%
6.4.2	A	We recommend delivery in a health care setting with obstetrics, neurology and intensive care unit present, and close postpartum monitoring in the case of a pregnant patient with VWM. Robinson et al., 2014 ^{e44} (level 4); Peter et al., 2008 ^{e45} (level 5); La Piana et al., 2012 ^{e46} (level 5)	100%

eTable 4. Detailed results of the eDelphi voting

Number	Strength	Total votes (n/n)	Strongly disagree (%)	Disagree (%)	Neutral (%)	Agree (%)	Strongly agree (%)
Diagnosis (avoiding false negative and false positive diagnoses)							
1.1	A	18/18	0.0%	0.0%	0.0%	0.0%	100%
1.2	B	18/18	0.0%	0.0%	0.0%	50%	50%
1.3	A	15/18	0.0%	0.0%	0.0%	0.0%	100%
1.4	A	15/18	0.0%	0.0%	0.0%	0.0%	100%
1.5	A	15/18	0.0%	0.0%	0.0%	13.3%	86.7%
1.6	A	15/18	0.0%	0.0%	0.0%	0.0%	100%
Prediction of disease course							
2.1	A	16/16	0.0%	0.0%	0.0%	0.0%	100%
2.2	A	16/16	0.0%	0.0%	0.0%	0.0%	100%
2.3	A	16/16	0.0%	0.0%	0.0%	0.0%	100%
2.4	A	16/16	0.0%	0.0%	0.0%	25%	75%
2.5.1	A	16/16	0.0%	0.0%	0.0%	12.5%	87.5%
2.5.2	B	16/16	0.0%	0.0%	0.0%	100%	0.0%
2.5.3	A	16/16	0.0%	0.0%	0.0%	12.5%	87.5%
2.5.4	A	16/16	0.0%	0.0%	0.0%	6.3%	93.8%
Measures to prevent episodes of rapid decline							
3.1	A	18/20	0.0%	5.6%	0.0%	0.0%	94.4%
3.2	A	17/20	0.0%	0.0%	5.9%	5.9%	88.2%
3.3	B	17/20	0.0%	0.0%	23.5%	35.3%	41.2%
3.4	B	17/20	0.0%	0.0%	0.0%	70.6%	29.4%
3.5	A	16/20	0.0%	0.0%	0.0%	0.0%	100%
3.6	A	16/20	0.0%	0.0%	0.0%	0.0%	100%
3.7	B	16/20	0.0%	0.0%	6.3%	43.8%	50.0%
3.8	A	16/20	0.0%	0.0%	0.0%	6.3%	93.8%
3.9	A	16/20	0.0%	0.0%	0.0%	12.5%	87.5%
3.10	A	16/20	0.0%	0.0%	6.3%	6.3%	87.5%
3.11	A	16/20	0.0%	0.0%	12.5%	6.3%	81.3%
3.12	B	16/20	0.0%	0.0%	12.5%	25.0%	62.5%
3.13	A	16/20	0.0%	0.0%	0.0%	0.0%	100%
3.14	A	16/20	0.0%	0.0%	0.0%	25.0%	75.0%
3.15	B	16/20	0.0%	0.0%	0.0%	43.8%	56.3%
Medication							
4.1	B	18/20	0.0%	11.1%	11.1%	50.0%	27.8%
4.2	A	18/20	0.0%	0.0%	5.6%%	11.1%	83.3%
Acute presentation management							
5.1	A	20/22	0.0%	5.0%	0.0%	5.0%	90.0%
5.2	A	20/22	5.0%	5.0%	10.0%	5.0%	75.0%
5.3	A	19/22	0.0%	0.0%	0.0%	0.0%	100%
5.4	C	19/22	0.0%	0.0%	47.4%	42.1%	10.5%
Chronic disease management							
6.1.1	A	18/20	0.0%	0.0%	5.6%	11.1%	83.3%
6.2.1	A	18/20	0.0%	0.0%	0.0%	0.0%	100%
6.3.1	A	20/21	0.0%	0.0%	0.0%	10.0%	90.0%
6.3.2	A	19/21	0.0%	0.0%	0.0%	0.0%	100%
6.3.3	A	18/21	0.0%	0.0%	0.0%	11.1%	88.9%
6.4.1	A	18/21	0.0%	0.0%	0.0%	0.0%	100%
6.4.2	A	18/21	0.0%	0.0%	0.0%	0.0%	100%

Note: Due to rounding, percentages may not add up to 100%.

eTable 5. List of disorders clinically mimicking VWM

Characteristic	Clinical look-a-likes
Acute clinical decline (e.g. acute motor deterioration and loss of consciousness)	Encephalopathy including due to acute disseminated encephalomyelitis (ADEM), acute necrotizing encephalopathy (ANE), Leigh syndrome, autoimmune encephalitis or infectious encephalitis.
Progressive motor decline with predominant ataxia	Hereditary ataxias such as spinocerebellar ataxia. Other leukodystrophies such as metachromatic leukodystrophy. Multiple sclerosis.
Chronic deterioration with insidious onset in adulthood	Dementia syndrome including Alzheimer and vascular dementia. Other adult-onset leukodystrophies such as metachromatic leukodystrophy and ALSP.

Note: This table is based on ^{e1,e2, e47}

eTable 6. overview of all known genetic variants associated with VWM to facilitate variant curation and diagnosis

Gene	DNA	Protein	References
(Likely) pathogenic variants			
EIF2B1^A	c.115+1G>A	p.?	e9
EIF2B1 ^A	c.253-23T>C	p.(Asp85Phefs*12)	e48
EIF2B1	c.323_325del	p.(Arg108del)	e19
EIF2B1	c.328A>G	p.(Lys110Glu)	e20
EIF2B1	c.439C>T	p.(Arg147*)	e49
EIF2B1 ^A	c.483-24A>G	p.?	e7
EIF2B1	c.547G>T	p.(Val183Phe)	e50
EIF2B1	c.620_622del	p.(Gly204del)	e51
EIF2B1	c.622A>T	p.(Asn208Tyr)	e9
EIF2B1	c.702G>C	p.(Lys234Asn)	ALC
EIF2B1	c.715T>G	p.(Phe239Val)	e21
EIF2B1	c.721C>G	p.(Leu241Val)	e7
EIF2B1	c.806G>A	p.(Arg269Gln)	e19
EIF2B1	c.812_813insT	p.(Trp272Valfs*28)	ALC
EIF2B1	c.824A>G	p.(Tyr275Cys)	e51
EIF2B1	c.833C>G	p.(Pro278Arg)	e16
EIF2B1	c.878C>T	p.(Pro293Leu)	e7
EIF2B1	c.911A>G	p.(Tyr304Cys)	e48
EIF2B2	c.1A>G	p.?	e5
EIF2B2	c.3G>A	p.?	ALC
EIF2B2	c.26C>A	p.(Ser9*)	ALC
EIF2B2	c.42del	p.(Ile15Serfs*8)	ALC
EIF2B2	c.254T>A	p.(Val85Glu)	e53
EIF2B2	C268C>T	p.(Arg90Trp)	e54
EIF2B2	c.397A>T	p.(Ile133Phe)	ALC
EIF2B2	c.496A > G	p.(Met166Val)	e41
EIF2B2	c.512C>T	p.(Ser171Phe)	e42
EIF2B2	c.514C>G	p.(Arg172*)	e7
EIF2B2 ^A	c.529_543del	p.(Phe177Ala181del)	e16
EIF2B2	c.547C>T	p.(Arg183*)	e42
EIF2B2 ^A	c.548del	p.(Arg183Glnfs*9)	e8
EIF2B2 ^A	c.551dup	p.(Arg185Glufs*18)	e16
EIF2B2	c.586C>T	p.(Pro196Ser)	e50
EIF2B2	c.599G>T	p.(Gly200Val)	e22
EIF2B2	c.599G>C	p.(Gly200Ala)	e3
EIF2B2 ^A	c.607_612delinsTG	p.(Met203Trpfs*2)	e8
EIF2B2	c.682A>G	p.(Arg228Gly)	e21
EIF2B2	c.638A>G	p.(Glu213Gly)	e8
EIF2B2	c.653C>T	p.(Thr218Ile)	e16
EIF2B2	c.677T>A	p.(Met226Lys)	e55
EIF2B2	c.817A>C	p.(Lys273Gln)	e56
EIF2B2	c.818A>G	p.(Lys273Arg)	e8
EIF2B2	c.818A>T	p.(Lys273Ile)	e7
EIF2B2	c.863T>C	p.(Phe288Ser)	e7
EIF2B2	c.871C>T	p.(Pro291Ser)	e22

EIF2B2	c.880G>T	p.(Val294Phe)	e48
EIF2B2	c.890del	p.(Phe297Serfs*43)	ALC
EIF2B2	c.899G>C	p.?	ALC
EIF2B2	c.910G>C	p.(Glu304*)	e3
EIF2B2	c.922G>A	p.(Val308Met)	e7
EIF2B2	c.926A>G	p.(His309Arg)	e7
EIF2B2 ^A	c.939_948del	p.(Asp314Profs*23)	e56
EIF2B2	c.947T>A	p.(Val316Asp)	e8
EIF2B2	c.995C>T	p.(Ala332Val)	e20
EIF2B2	c.976T>C	p.(Ser326Pro)	e57
EIF2B2	c.986G>T	p.(Gly329Val)	e8
EIF2B3	c.28G>C	p.(Val10Leu)	ALC
EIF2B3	c.32G>T	p.(Gly11Val)	e51
EIF2B3	c.40T>C	p.(Ser14Pro)	e7
EIF2B3	c.41C>T	p.(Ser14Phe)	e58
EIF2B3	c.43C>T	p.(Arg15Trp)	e59
EIF2B3	c.74A>G	p.(Lys25Arg)	e48
EIF2B3	c.80T>A	p.(Leu27Gln)	e59
EIF2B3	c.89T>C	p.(Val30Ala)	e60
EIF2B3	c.97A>G	p.(Lys33Glu)	e61
EIF2B3	c.136G>A	p.(Val46Ile)	e3
EIF2B3	c.140G>A	p.(Gly47Glu)	e25
EIF2B3	c.144T>A	p.(Phe48Leu)	e48
EIF2B3	c.179_187del	p.(Gln60_Alala62del)	e7
EIF2B3 ^A	c.260C>T	p.(Ala87Val)	e9
EIF2B3	c.260C>A	p.(Ala87Glu)	e59
EIF2B3	c.272G>A	p.(Arg91His)	e48
EIF2B3	c.319G>A	p.(Asp107Asn)	e7
EIF2B3	c.344A>C	p.(His115Pro)	e7
EIF2B3	c.391 T>G	p.(Leu131Val)	e52
EIF2B3	c.407A>C	p.(Gln136Pro)	e3
EIF2B3 ^A	c.450dupA	p.(A151Serfs*6)	e62
EIF2B3 ^A	c.455-1G>T	p.?	e63
EIF2B3	c.503T>C	p.(Leu168Pro)	e60
EIF2B3	c.521C>A	p.(Ala174Glu)	e7
EIF2B3	c.562C>T	p.(Gln188Tyr) ^B	e57
EIF2B3	c.566+1_567-1	p.?	ALC
EIF2B3	c.602A>G	p.(Asp201Gly)	e48
EIF2B3	c.604G>A	p.(Ala202Thr)	e64
EIF2B3 ^A	r.657-975del	p.(Ser220Cysfs*56)	e7
EIF2B3	c.673C>T	p.(Arg225Trp)	e65
EIF2B3 ^A	c.674G>A	p.(Arg225Gln)	e9
EIF2B3	c.686T>G	p.(Ile229Ser)	e66
EIF2B3	c.687T>G	p.(Ile229Met)	e16
EIF2B3	c.706C>G	p.(Gln236Glu)	e57
EIF2B3	c.856C>T	p.(Arg286*)	e7
EIF2B3	c.893T>G	p.(Val298Gly)	e7
EIF2B3	c.934C>T	p.(Arg312*)	ALC
EIF2B3	c.935G>A	p.(Arg312Gln)	e20
EIF2B3	c.965C>G	p.(Ala322Gly)	e20

EIF2B3	c.956A>G	p.(Tyr319Cys)	e52
EIF2B3	c.1004C>T	p.(Pro335Leu)	e48
EIF2B3	c.1022A>G	p.(His341Arg)	ALC
EIF2B3	c.1023T>G	p.(His341Gln)	e3
EIF2B3	c.1037T>C	p.(Ile346Thr)	e20
EIF2B3	c.1106_1113del	p.(Ser369Cysfs*404)	e20
EIF2B3	c.1118C>T	p.(Ser373Leu)	e51
EIF2B3	c.1124T>G	p.(Ile375Ser)	e16
EIF2B3	c.1153G>T	p.(Val385Leu)	e7
EIF2B3 ^A	c.1193_1194del	p.(Val398Glyfs*35)	e9
EIF2B3	c.1261A>T	p.(Ile421Phe)	e66
EIF2B3	c.1312C>T	p.(Arg438*)	e58
EIF2B4	c.134A>G	p.(Gln45Arg)	e7
EIF2B4	c.418+1G>A	p.?	ALC
EIF2B4	c.487G>A	p.(Glu163Lys)	ALC
EIF2B4 ^A	c.498+3del	p.?	e67
EIF2B4 ^A	c.499-1G>C	p.(Val167Hisfs*47)	e48
EIF2B4	c.556T>A	p.(Tyr186Asn)	e21
EIF2B4	c.610C>T	p.(His204Tyr)	ALC
EIF2B4	c.614C>T	p.(Pro205Leu)	e68
EIF2B4	c.617T>C	p.(Met206Thr)	e69
EIF2B4	c.622G>A	p.(Val208Met)	ALC
EIF2B4	c.625C>T	p.(Arg209*)	e50
EIF2B4	c.626G>A	p.(Arg209Gln)	e3
EIF2B4 ^A	c.631G>T	p.(Gly211Cys)	e70
EIF2B4	c.639G>C	p.(Gln213His)	ALC
EIF2B4	c.673C>T	p.(Arg225Trp)	ALC
EIF2B4 ^A	c.683C>T	p.(Ala228Val)	e9
EIF2B4 ^A	c.728C>T	p.(Pro243Leu)	e3
EIF2B4	c.788T>C	p.(Leu263Pro)	ALC
EIF2B4	c.800G>A	p.(Arg267His)	ALC
EIF2B4	c.806T>G	p.(Leu269Arg)	e50
EIF2B4 ^A	c.883_885del	p.(Glu295del)	e16
EIF2B4 ^A	C.885+2T>G	p.?	e62
EIF2B4 ^A	c.877_879del	p.(Glu293del)	e16
EIF2B4	c.884A>T	p.?	ALC
EIF2B4	c.920A>G	p.(Tyr307Cys)	ALC
EIF2B4	c.935T>C	p.(Ile312Thr)	e48
EIF2B4 ^A	c.977_979del	p.(Lys326del)	e7
EIF2B4	c.978G>C	p.(Lys326Asn)	e7
EIF2B4	c.1069C>T	p.(Arg357Trp)	e3
EIF2B4 ^A	c.1070G>A	p.(Arg357Gln)	e9
EIF2B4	c.1075G>C	p.(Val359Leu)	ALC
EIF2B4	c.1090C>T	p.(Arg364Trp)	e48
EIF2B4 ^A	c.1091G>A	p.(Arg364Gln)	e3
EIF2B4 ^A	c.1120C>T	p.(Arg374Cys)	e9
EIF2B4	c.1121G>T	p.(Arg374Leu)	e48
EIF2B4	c.1129G>C	p.(Val377Leu)	ALC
EIF2B4	c.1172C>A	p.(Ala391Asp)	e22
EIF2B4 ^A	c.1191+1G>A	p.(Cys338Trpfs*17)	e9

EIF2B4	c.1198A>C	p.(Lys400Gln)	e57
EIF2B4	c.1298C>T	p.(Pro433Leu)	e71
EIF2B4 ^A	c.1304T>C	p.(Leu435Pro)	e70
EIF2B4 ^A	c.1337G>A	p.(Arg446His)	e72
EIF2B4	c.1346C>T	p.(Thr449Ile)	e64
EIF2B4	c.1352C>G	p.(Ala451Gly)	e7
EIF2B4 ^A	c.1370+1insT	p.?	e16
EIF2B4	c.1393T>C	p.Cys465Arg	e42
EIF2B4	c.1399C>T	p.(Arg467Trp)	e51
EIF2B4	c.1400G>C	p.(Arg467Pro)	ALC
EIF2B4	c.1400G>T	p.(Arg467Leu)	e48
EIF2B4	c.1441T>C	p.(Ser481Pro)	e73
EIF2B4	c.1447C>T	p.(Arg483Trp)	e22
EIF2B4	c.1457A>G	p.(Asn486Ser)	ALC
EIF2B4	c.1462G>A	p.(Val488Ile)	ALC
EIF2B4 ^A	c.1465T>C	p.(Tyr489His)	e42
EIF2B4	c.1537C>A	p.(Pro513Thr)	ALC
EIF2B5	c.5C>T	p.(Ala2Val)	e48
EIF2B5	c.47C>A	p.(Ala16Asp)	e3
EIF2B5	c.116_130del	p.(Pro39_leu43del)	e7
EIF2B5	c.161G>C	p.(Arg54Pro)	ALC
EIF2B5	c.162G>C	p.(Arg54Pro)	e3
EIF2B5	c.166T>G	p.(Phe56Val)	e3
EIF2B5	c.167T>C	p.(Phe56Ser)	e16
EIF2B5	c.173C>G	p.(Pro58Arg)	ALC
EIF2B5	c.185A>T	p.(Asp62Val)	e25
EIF2B5	c.200_206del	p.(Leu67Profs*7)	e7
EIF2B5	c.203T>C	p.(Leu68Ser)	e50
EIF2B5	c.206G>T	p.(Arg269Leu)	ALC
EIF2B5	c.217G>A	p.(Val73Met)	e16
EIF2B5	c.218T>G	p.(Val73Gly)	e8
EIF2B5	c.220G>A	p.(Ala74Thr)	e50
EIF2B5	c.230A>G	p.(Asp77Gly)	e7
EIF2B5	c.233A>C	p.(Tyr78Ser)	e51
EIF2B5	c.235A>C	p.(Thr79Pro)	e57
EIF2B5	c.236C>T	p.(Thr79Ile)	e16
EIF2B5	c.241G>A	p.(Glu81Lys)	e3
EIF2B5	c.247del	p.(Leu83*)	e7
EIF2B5	c.250del	p.(Thr84Leufs*24)	e7
EIF2B5 ^A	c.251C>T	p.(Thr84Ile)	e48
EIF2B5	c.271A>G	p.(Thr91Ala)	e8
EIF2B5 ^A	c.274T>A	p.(Phe92Ile)	e48
EIF2B2	c.380T>C	p.(Leu127Pro)	e16
EIF2B5 ^A	c.304dup	p.(Ile102Asnfs*36)	e27
EIF2B5 ^A	c.314A>G	p.(His105Arg)	e48
EIF2B5	c.318A>T	p.(Leu106Phe)	e8
EIF2B5	c.328_329del	p.(Lys110Valfs*27)	ALC
EIF2B5	c.331T>C	p.(Trp111Arg)	e16
EIF2B5	c.337C>T	p.(Arg113Cys)	e3
EIF2B5	c.338G>A	p.(Arg113His)	e8

EIF2B5	c.380T>C	p.(Leu127Pro)	e16
EIF2B5	C.385C>T	p.(Arg129*)	e27
EIF2B5	c.395G>C	p.(Gly132Ala)	e48
EIF2B5	c.406C>T	p.(Arg136Cys)	e3
EIF2B5	c.407G>A	p.(Arg136His)	e48
EIF2B5	c.409G>C	p.(Asp137His)	e57
EIF2B5	c.449T>G	p.(Leu150Arg)	e74
EIF2B5	c.453_454del	p.(Tyr152Trpfs*13)	e50
EIF2B5	c.457G>A	p.(Gly153Arg)	e7
EIF2B5	c.468C>G	p.(Ile156Met)	e16
EIF2B5	c.475A>G	p.(Ile159Val)	e7
EIF2B5	c.511A>G	p.(Arg171Gly)	e48
EIF2B5	c.512G>A	p.(Arg171Lys)	e59
EIF2B5	c.530dup	p.(Asn177Lysfs*31)	ALC
EIF2B5	c.536C >T	p.(Ser179Phe)	e57
EIF2B5	c.545C>T	p.(Thr182Met)	e75
EIF2B5	c.562T>A	p.(Ser188Thr)	e48
EIF2B5	c.573C>T	p.(Thr182Met)	e75
EIF2B5	c.578A>T	p.(Pro193Leu)	e48
EIF2B5	c.583C>T	p.(Arg195Cys)	e42
EIF2B5	c.584G>A	p.(Arg195His)	e76
EIF2B5	c.592G>A	p.(Glu198Lys)	e3
EIF2B5	c.626G>A	p.(Arg209Gln)	e50
EIF2B5	c.631A>G	p.(Arg211Gly)	e48
EIF2B5	c.633G>T	p.(Arg211Ser)	e27
EIF2B5	c.641A>G	p.(His214Arg)	e24
EIF2B5	c.664C>T	p.(Arg222Trp)	ALC
EIF2B5	c.683T>C	p.(Leu228Pro)	ALC
EIF2B5 ^A	c.685-13C>G	p.(Ser229Gln255del)	e16
EIF2B5	c.713T>A	p.(Val238Glu)	e48
EIF2B5	c.725A>G	p.(Tyr242Cys)	e77
EIF2B5	c.743A>T	p.(His248Leu)	e24
EIF2B5	c.746 T>G	p.(Ile249Ser)	e77
EIF2B5	c.758C>A	p.(Ser253Tyr)	e16
EIF2B5	c.764A>C	p.(Gln255Pro)	ALC
EIF2B5	c.766-1G>A	p.(Gln256Glu281del)	e78
EIF2B5 ^A	c.792delinsACA	p.(Phe264Leufs*15)	e8
EIF2B5	c.805C>T	p.(Arg269*)	e51
EIF2B5	c.805C>G	p.(Arg269Gly)	e50
EIF2B5	c.806G>A	p.(Arg269Gln)	e79
EIF2B5	c.806G>T	p.(Arg269Leu)	e3
EIF2B5	c.806G>C	p.(Arg269Pro)	ALC
EIF2B5	c.808G>C	p.(Asp270His)	e59
EIF2B5	c.860T>A	p.(Ile287Asn)	e7
EIF2B5	c.862C>G	p.(His288Asp)	ALC
EIF2B5	c.895C>T	p.(Arg299Cys)	ALC
EIF2B5	c.896G>A	p.(Arg299His)	e8
EIF2B5	c.911A>C	p.(His304Pro)	e51
EIF2B5	c.913A>T	p.(Met305Leu)	e43
EIF2B5	c.915G>A	p.(Met305Ile)	e20

EIF2B5	c.925G>C	p.(Val309Leu)	e80
EIF2B5	c.929G>T	p.(Cys310Phe)	e50
EIF2B5	c.935A>G	p.(Asp312Gly)	e51
EIF2B5	c.943C>G	p.(Arg315Gly)	e8
EIF2B5	c.943C>T	p.(Arg315Cys)	e3
EIF2B5	c.944G>A	p.(Arg315His)	e8
EIF2B5	c.947G>A	p.(Arg316Gln)	e7
EIF2B5	c.952G>A	p.(Val318Ile)	e51
EIF2B5	c.956A>G	p.(Tyr319Cys)	e7
EIF2B5	c.967C>T	p.(Pro323Ser)	e3
EIF2B5	c.968C>T	p.(Pro323Leu)	ALC
EIF2B5	c.981del	p.(Phe327Leufs*30)	ALC
EIF2B5 ^A	c.997del	p.(Gln333Argfs*24)	e48
EIF2B5	c.1003T>C	p.(Cys335Arg)	e50
EIF2B5	c.1004G>C	p.(Cys335Ser)	e25
EIF2B5	c.1006A>C	p.(Thr336Pro)	ALC
EIF2B5	c.1010A>G	p.(His337Arg)	e59
EIF2B5	c.1015G>T	p.(Arg339Trp)	e8
EIF2B5	c.1016G>A	p.(Arg339Gln)	e8
EIF2B5	c.1016G>T	p.(Arg339Pro)	e20
EIF2B5 ^A	c.1022_1024del	p.(Asn341del)	e16
EIF2B5	c.1025T>C	p.(Ile342Thr)	e66
EIF2B5	c.1028A>G	p.(Tyr343Cys)	e3
EIF2B5 ^A	c.1444+19G>A	p.(Tyr483Valfs*49)	e48
EIF2B5	c.1048_1064delins13	p.(Leu350Ilefs*6)	ALC
EIF2B5	c.1049T>C	p.(Leu350Pro)	e48
EIF2B5	c.1051G>A	p.(Gly351Ser)	e7
EIF2B5	c.1054C>T	p.(His352Tyr)	e66
EIF2B5	c.1087G>A	p.(Gly363Ser)	e66
EIF2B5	c.1126A>G	p.(Asn376Asp)	e25
EIF2B5	c.1129del	p.(Ser377Valfs*47)	ALC
EIF2B5	c.1153A>G	p.(Ile385Val)	e3
EIF2B5	c.1154T>C	p.(Ile385Thr)	e21
EIF2B5	c.1156+13G>A	p.?	e77
EIF2B5	c.1157G>T	p.(Gly386Val)	e8
EIF2B5	c.1157G>A	p.?	e81
EIF2B5	c.1160T>G	p.(Asp387Gly)	e3
EIF2B5	c.1165G>A	p.(Val389Met)	e82
EIF2B5	c.1201C>T	p.(Arg401*)	e7
EIF2B5	c.1208C>T	p.(Ala403Val)	e16
EIF2B5	c.1223T>C	p.(Ile408Thr)	e83
EIF2B5	c.1241G>A	p.(Cys414Tyr)	e57
EIF2B5	c.1244A>G	p.(Asp415Gly)	e16
EIF2B5	c.1254G>C	p.(Glu418Asp)	e16
EIF2B5	c.1264C>T	p.(Arg422*)	e8
EIF2B5	c.1274T>G	p.(Leu425Arg)	e3
EIF2B5	c.1280C>T	p.(Pro427Leu)	e3
EIF2B5	c.1289T>C	p.(Val430Ala)	e8
EIF2B5	c.1295C>T	p.(Thr432Ile)	e7
EIF2B5	c.1306G>T	p.(Val436Phe)	ALC

EIF2B5	c.1309G>A	p.(Val437Met)	e48
EIF2B5	c.1340C>T	p.(Ser447Leu)	e22
EIF2B5	c.1352T>C	p.(Leu451Ser)	e57
EIF2B5	c.1355A>G	p.(His452Arg)	ALC
EIF2B5	c.1360C>T	p.(Pro454Ser)	e16
EIF2B5 ^A	c.1444Gins17	p.?	e3
EIF2B5 ^A	c.1444+19G>A	p.(Tyr483Val fs48*)	e48
EIF2B5	c.1448A>G	p.(Tyr483Cys)	e24
EIF2B5	c.1459G>A	p.(Glu487Lys)	e16
EIF2B5	c.1463T>C	p.(Val488Ala)	ALC
EIF2B5	c.1484A>G	p.(Tyr495Cys)	e22
EIF2B5	c.1518del	p.(Glu506_fs*52)	e20
EIF2B5	c.1543T>G	p.(Trp515Gly)	ALC
EIF2B5 ^A	c.1546+1G>T	p.?	e7
EIF2B5	c.1688G>A	p.(Arg563Gln)	e84
EIF2B5	c.1694delAins45	p.(Lys565Ilefs*3)	e85
EIF2B5	c.1706T>C	p.(Ile569Thr)	ALC
EIF2B5	c.1745+5G>A	p.(Tyr583*)	e48
EIF2B5	c.1810C>T	p.(Pro604Ser)	e16
EIF2B5 ^A	c.1813del	p.(Leu605Cysfs*21)	e86
EIF2B5	c.1824G>A	p.(Met608Ile)	e48
EIF2B5	c.1827_1838del	p.(Ser620Asp623del)	e25
EIF2B5	c.1827_1838del	p.(610_613del4)	e20
EIF2B5	c.1841C>G	p.(Ser614*)	ALC
EIF2B5	c.1850A>G	p.(Tyr617Cys)	e59
EIF2B5	c.1882T>C	p.(Trp628Arg)	e8
EIF2B5	c.1884G>A	p.(Trp628*)	e3
EIF2B5	c.1903T>C	p.(Tyr635His)	ALC
EIF2B5	c.1946T>C	p.(Ile649Thr)	e16
EIF2B5	c.1948G>A	p.(Glu650Lys)	e8
EIF2B5	c.1996_2016del	p.(Val666Gln672)	e3
EIF2B5	c.1996-2A>G	p.?	ALC
EIF2B5	c.2051G>C	p.(Trp684Ser)	e48
EIF2B5 ^A	c.2081del	p.(Gly694Alfs*17)	e58
Variants with uncertain link to VWM			
EIF2B1	c.868G>A	p.(Val290Met)	e59
EIF2B2	c.76G>A	p.(Gly26Ser)	e87
EIF2B2	c.591C>G	p.(Phe197Leu)	e88
EIF2B2	c.803G>A	p.(Cys268Tyr)	e89
EIF2B2	c.826C>T	p.(Pro276Ser)	ALC
EIF2B3	c.22A>T	p.(Met8Leu)	e90
EIF2B3	c.130G>A	p.(Val40Ile)	e66
EIF2B3	c.464G>A	p.(Arg115His)	e91
EIF2B3	c.937G>A	p.(Val313Met)	e92
EIF2B3	c.1270T>G	p.(Cys424Gly)	e93
EIF2B4	c.259G>A	p.(Ala87Thr)	ALC
EIF2B4	c.818T>C	p.(Met273Thr)	e24
EIF2B4 ^A	c.823A>T	p.(Asn275Tyr)	e57
EIF2B4	c.1339G>A	p.(Val447Met)	e7
EIF2B5	c.389C>T	p.(Ser130Leu)	e27

<i>EIF2B5</i>	c.461A>G	p.(Asp154Gly)	e92
<i>EIF2B5</i>	c.877G>T	p.(Ala293Ser)	ALC
<i>EIF2B5</i> ^A	c.1302+59A>G	p.?	e58
<i>EIF2B5</i>	c.1450A>C	p.(Asn484His)	e27
<i>EIF2B5</i>	c.1869+11A>G	p.?	ALC
<i>EIF2B5</i> ^A	c.1913G>A	p.(Arg638His)	e94

Note. The table is organized by ascending sequence of mutation. Reference sequences of *EIF2B1*, *EIF2B2*, *EIF2B3*, *EIF2B4* and *EIF2B5* are NM_001414.3, NM_014239.3, NM_020365.4, NM_0010341161.1, and NM_003907.2, respectively. The table is organized by ascending sequence of mutation. Reference sequences of *EIF2B1*, *EIF2B2*, *EIF2B3*, *EIF2B4* and *EIF2B5* are NM_001414.3, NM_014239.3, NM_020365.4, NM_0010341161.1, and NM_003907.2, respectively. The table contains all pathogenic and likely pathogenic variants in *EIF2B1-5* genes from the 2010 last variant update^{e48} up to October 2024, supplemented by variants from the VWM database of the Amsterdam Leukodystrophy Center (ALC) and an extensive literature search using the Franklin Tool (franklin.genoox.com. Accessed September 1, 2024). The ALC database includes patients with VWM diagnoses established via both MRI and genetic testing. Allele frequencies and prevalence in homozygous state were checked using Genome Aggregation Database (gnomAD, gnomad.broadinstitute.org. Accessed September 1, 2024) to interpret unclassified variants from outside the ALC database. Unclassified variants were further interpreted using in-silico tools: Polymorphism Phenotyping v2 (PolyPhen-2, genetics.bwh.harvard.edu/pph2. Accessed September 1, 2024), Sorting Intolerant From Tolerant (SIFT, sift.bii.a-star.edu.sg. Accessed September 1, 2024 and Rare Exome Variant Ensemble Learner (REVEL, sites.google.com/site/revelgenomics. Accessed September 1, 2024). Effects on RNA splicing were predicted using the software Alamut Visual Plus version 1.11 (Interactive Biosoftware, Rouen, France). All variants were classified based on the American College of Medical Genetics and Genomics (ACMG)/Association for Molecular Pathology (AMP) guidelines⁹⁵. ^A Variants are amended at DNA and/or protein level from original publication in order to follow the current HGVS guidelines and match the positions in the current reference sequences.

eTable 7. List of clinically used drugs that were investigated for their effect on the ISR and references

Drug type	Name	Study design	Cell / tissue/ organ / species	ISR effect	References
Anesthetics	Isoflurane ^{ISR act}	In vivo / in vitro	Rat hippocampus	↑ATF4, CHOP, p-eIF2α	e96
Anesthetics	Isoflurane ^{ISR act}	In vivo / in vitro	Rat hippocampus	↑ATF4, CHOP, p-eIF2α	e97
Anesthetics	Isoflurane ^{ISR act}	In vivo	Yeast	↑ATF4, p-eIF2α	e98
Anesthetics	Sevoflurane ^{ISR act}	In vivo / in vitro	Mouse hippocampus	↑ATF4, CHOP, p-eIF2α	e99
Anesthetics	Sevoflurane ^{ISR act}	In vivo / in vitro	Mouse pups cerebral cortex	↑ATF4, CHOP, p-eIF2α	e100
Anesthetics	Halothane ^{ISR act}	In vivo	Rat liver cells	↑p-eIF2α, ↓eIF2B activity	e101
Anesthetics	Lidocaine ^{ISR act}	In vitro	Neuroblastoma cell line	↑ATF4, CHOP	e102
Anesthetics	Lidocaine ^{ISR act} , Ropivacaine ^{ISR act} , Levobupivacaine ^{ISR act} , Bupivacaine ^{ISR act} , Prilocaine ^{ISR act} , Chloroprocaine ^{ISR act}	In vitro	Osteosarcoma cell line	↑ATF4, p-eIF2α	e103
Anesthetic	Propofol + intralipid emulsion ^{ISR inh}	In vivo	Neuroblastoma cell line, experience in VWM patients	↓ATF4	e104
Antacid	Omeprazole ^{ISR quest}				-
Antacid	Esomeprazole ^{ISR quest}				-
Antibiotic	Azithromycin ^{ISR act}	In vitro	Rat adrenal gland cell line; fibrosarcoma cell line	↑ATF4, CHOP, p-eIF2α	e105
Antibiotic	Doxycycline ^{ISR act}	In vitro	Human colon adenocarcinoma cell line; human hepatocytes; breast cancer cell line	↑AFT4, CHOP	e106
Antibiotic	Doxycycline ^{ISR act}	In vitro	Mouse kidney and liver tissue	↑ATF4, CHOP, p-eIF2α	e107
Antibiotic	Minocycline ^{ISR quest}				Inconclusive results e106,e108
Antidepressants	Fluoxetine ^{ISR quest}				Inconclusive results e109,e110
Antidepressant	Vortioxetine ^{ISR inh}	In vivo / in vitro	Rat hippocampal and cortical tissues	↓ATF4, CHOP, p-eIF2α	e111
Antidepressant	Trazodon ^{ISR inh}	In vivo / in vitro	Chinese hamster ovary cell line	↓ATF4, CHOP	e112

Antiepileptic	Carbamazepine ^{ISR act}	In vitro	Human and mouse primary hepatocytes	↑ATF4 , CHOP	e113
Antiepileptic	Valproic acid ^{ISR quest}				Inconclusive results ^{e144-e117}
Antiepileptic	Phenobarbital ^{ISR quest}				-
Antiepileptic	Lamotrigine ^{ISR quest}				-
Antiepileptic	Levetiracetam ^{ISR quest}				-
Antiepileptic	Vigabatrin ^{ISR quest}				-
Antihypertensive	Propranolol ^{ISR quest}				-
Antihypertensive	Valsartan ^{ISR quest}				Inconclusive results ^{e118,e119}
Antipsychotic	Haldol ^{ISR quest}				-
Antipsychotic	Olanzapine ^{ISR act}	In vivo / in vitro	Neuroblastoma cell line; rat hypothalamus	↑ATF4, p-eIF2α	e120
Antipsychotic	Clozapine ^{ISR act} , Haloperidol ^{ISR act} , Olanzapine ^{ISR act}	In vivo / in vitro	Immortalized human hepatocyte cell line; rat liver	↑ATF4, CHOP	e121
Antipsychotic	Thioridazine ^{ISR act}	In vivo / in vitro	Mouse colorectal cancer cell line	↑ATF4, CHOP, p-eIF2α	e122
Antipyretic	Acetaminophen ^{ISR act} / Paracetamol ^{ISR act}	In vivo/ in vitro	Luciferase transgenic mice	↑ATF4, CHOP, p-eIF2α	e123 Chronic treatment for 18 days
Antipyretic	Aspirin ^{ISR quest}				Inconclusive results ^{e124,e125}
Antipyretic	Sodium salicylate ^{ISR quest}				Inconclusive results ^{126e126-128e128}
Corticosteroid	Dexamethasone ^{ISR inh}	In vitro	Human trabecular meshwork cells	↓ATF4, CHOP	e129
Corticosteroid	Methyl-prednisolone ^{ISR quest}				-
Corticosteroid	Prednisolone ^{ISR quest}				-
NSAID	Ibuprofen ^{ISR quest}	In vitro	Neuroblastoma cell line		Inconclusive result ^{e130}
NSAID	Naproxen ^{ISR quest}	In vitro	Skin carcinoma cell line		Inconclusive result ^{e131}
NSAID	Diclofenac ^{ISR act}	In vitro	Human and mouse primary hepatocytes	↑ATF4 , CHOP	e113
NSAID	Indomethacin ^{ISR act}	In vitro	Primary gastric mucosal cell line	↑ATF4, CHOP	e132
NSAID	Indomethacin ^{ISR act} diclofenac ^{ISR act}	In vitro	Colorectal adenocarcinoma cell line	↑ATF4, CHOP, p-eIF2α	e133
NSAID	Celecoxib ^{ISR act}	In vitro	Gastric carcinoma cell line	↑ATF4, CHOP, p-eIF2α	e134

NSAID	Celecoxib ^{ISR act}	In vitro	Gastric carcinoma cell line	↑ATF4, CHOP, p-eIF2α,	e135
NSAID	Celecoxib ^{ISR act}	In vitro	Gastric carcinoma cell line	↑ATF4, CHOP, p-eIF2α	e136
NSAID	Celecoxib ^{ISR act}	In vitro	Liver tumor cell line	↑ATF4, CHOP	e137
NSAID	Tolfenamic acid ^{ISR act}	In vitro	Colorectal cancer cell line	↑ATF4, CHOP	e138
Opioid	Morphine ¹	In vivo / in vitro	Rat dorsal root ganglions	↑ATF4, CHOP	e139
Opioid	Oxycodone ^{ISR act}	In vivo / in vitro	Rat nucleus accumbens, cortex and brainstem; breast cancer cell line	↑ATF4, p-eIF2α	e140
Opioid	Oxycodone ^{ISR act}	In vivo / in vitro	Rats whole brain tissue; breast cancer cell line	↑ATF4, CHOP, p-eIF2α	e141
Opioid	Sufentanil ^{ISR quest}	In vivo / in vitro	Rat hepatic ischemia/ reperfusion model		Inconclusive result ^{e142}
Sedative	Alimemazine ^{ISR quest}				-
Sedative	Dexmedetomidine ^{ISR quest}				Inconclusive results ^{e143-e145}
Sedative	Diazepam ^{ISR quest}				-
Sedative	Clonazepam ^{ISR quest}				-
Sedative	Clobazam ^{ISR quest}				-
Sedative	Midazolam ^{ISR quest}				Inconclusive results ^{e146,e147}
Sedative	Oxazepam ^{ISR quest}				-
Sedative	Temazepam ^{ISR quest}				-
Spasmolytic	Baclofen ^{ISR neutr}	In vitro	Primary rat retinal ganglion cells	↓ATF4, CHOP, p-eIF2α	Does not readily cross the BBB ^{e148}

Note: **Red**^{ISR act}, ISR activating; **green**^{ISR inh}, ISR inhibiting; **grey**^{ISR quest}, ISR effect not investigated or equivocal findings; **blue**^{ISR neutr}, neutral ISR effect

eReferences

- e1. Stellingwerff MD, Al-Saady ML, van de Brug T, Barkhof F, Pouwels PJW, van der Knaap MS. MRI Natural History of the Leukodystrophy Vanishing White Matter. *Radiology* 2021;300:671-680.
- e2. Stellingwerff MD, van de Wiel MA, van der Knaap MS. Radiological correlates of episodes of acute decline in the leukodystrophy vanishing white matter. *Neuroradiology* 2023;65:855-863.
- e3. Fogli A, Schiffmann R, Bertini E, et al. The effect of genotype on the natural history of eIF2B-related leukodystrophies. *Neurology* 2004;62:1509-1517.
- e4. Aygnac X, Carra-Dalliere C, Menjot de Champfleury N, et al. Adult-onset genetic leukoencephalopathies: a MRI pattern-based approach in a comprehensive study of 154 patients. *Brain* 2015;138:284-292.
- e5. van der Lei HD, Steenweg ME, Barkhof F, et al. Characteristics of early MRI in children and adolescents with vanishing white matter. *Neuropediatrics* 2012;43:22-26.
- e6. Mahdiah N, Soveizi M, Tavasoli AR, et al. Genetic testing of leukodystrophies unraveling extensive heterogeneity in a large cohort and report of five common diseases and 38 novel variants. *Sci Rep* 2021;11:3231.
- e7. Slynko I, Nguyen S, Hamilton EMC, et al. Vanishing white matter: Eukaryotic initiation factor 2B model and the impact of missense mutations. *Mol Genet Genomic Med* 2021;9:e1593.
- e8. Leegwater PA, Vermeulen G, Konst AA, et al. Subunits of the translation initiation factor eIF2B are mutant in leukoencephalopathy with vanishing white matter. *Nat Genet* 2001;29:383-388.
- e9. van der Knaap MS, Leegwater PA, Konst AA, et al. Mutations in each of the five subunits of translation initiation factor eIF2B can cause leukoencephalopathy with vanishing white matter. *Ann Neurol* 2002;51:264-270.
- e10. Labauge P. Magnetic resonance findings in leukodystrophies and MS. *Int MS J* 2009;16:47-56.
- e11. Köhler W, Curiel J, Vanderver A. Adulthood leukodystrophies. *Nat Rev Neurol* 2018;14:94-105.
- e12. Patay Z. Diffusion-weighted MR imaging in leukodystrophies. *Eur Radiol* 2005;15:2284-2303.
- e13. Khorrami M, Khorram E, Yaghini O, et al. Identification of a Missense Variant in the EIF2B3 Gene Causing Vanishing White Matter Disease with Antenatal-Onset but Mild Symptoms and Long-Term Survival. *J Mol Neurosci* 2021;71:2405-2414.
- e14. Tian Y, Liu Q, Zhou Y, et al. Identification of a Novel Heterozygous Mutation in the EIF2B4 Gene Associated With Vanishing White Matter Disease. *Front Bioeng Biotechnol* 2022;10:901452.
- e15. Deginet E, Tilahun R, Bishaw S, Eshetu K, Moges A. Probable Vanishing White Matter Disease: A Case Report and Literature Review. *Ethiop J Health Sci* 2021;31:1307-1310.
- e16. Pronk JC, van Kollenburg B, Scheper GC, van der Knaap MS. Vanishing white matter disease: a review with focus on its genetics. *Ment Retard Dev Disabil Res Rev* 2006;12:123-128.
- e17. van der Knaap MS, Fogli A, Boespflug-Tanguy O, Abbink TEM, Schiffmann R. Childhood Ataxia with Central Nervous System Hypomyelination / Vanishing White Matter. *GeneReviews*(®) 2003.
- e18. Hamilton EMC, van der Lei HDW, Vermeulen G, et al. Natural History of Vanishing White Matter. *Ann Neurol* 2018;84:274-288.
- e19. Güngör G, Güngör O, Çakmaklı S, et al. Vanishing white matter disease with different faces. *Childs Nerv Syst* 2020;36:353-361.
- e20. Zhang H, Dai L, Chen N, et al. Fifteen novel EIF2B1-5 mutations identified in Chinese children with leukoencephalopathy with vanishing white matter and a long term follow-up. *PLoS One* 2015;10:e0118001.
- e21. Shimada S, Shimojima K, Sangu N, et al. Mutations in the genes encoding eukaryotic translation initiation factor 2B in Japanese patients with vanishing white matter disease. *Brain Dev* 2015;37:960-966.
- e22. van der Knaap MS, van Berkel CG, Herms J, et al. eIF2B-related disorders: antenatal onset and involvement of multiple organs. *Am J Hum Genet* 2003;73:1199-1207.
- e23. van der Lei HD, van Berkel CG, van Wieringen WN, et al. Genotype-phenotype correlation in vanishing white matter disease. *Neurology* 2010;75:1555-1559.

- e24. Labauge P, Horzinski L, Ayrignac X, et al. Natural history of adult-onset eIF2B-related disorders: a multi-centric survey of 16 cases. *Brain* 2009;132:2161-2169.
- e25. Wu Y, Pan Y, Du L, et al. Identification of novel EIF2B mutations in Chinese patients with vanishing white matter disease. *J Hum Genet* 2009;54:74-77.
- e26. Zhou L, Zhang H, Chen N, et al. Similarities and differences between infantile and early childhood onset vanishing white matter disease. *J Neurol* 2018;265:1410-1418.
- e27. Ren Y, Yu X, Chen B, et al. Genotypic and phenotypic characteristics of juvenile/adult onset vanishing white matter: a series of 14 Chinese patients. *Neurol Sci* 2022;43:4961-4977.
- e28. van der Knaap MS, Pronk JC, Scheper GC. Vanishing white matter disease. *Lancet Neurol* 2006;5:413-423.
- e29. Pakos-Zebrucka K, Koryga I, Mnich K, Ljubic M, Samali A, Gorman AM. The integrated stress response. *EMBO Rep* 2016;17:1374-1395.
- e30. Wek RC, Anthony TG, Staschke KA. Surviving and Adapting to Stress: Translational Control and the Integrated Stress Response. *Antioxid Redox Signal* 2023;39:351-373.
- e31. Vinogradsky EI, Otallah SI. Vanishing White Matter Disease Diagnosis After Athletic Concussion in an Adolescent Male Patient. *Clin J Sport Med* 2021;31:e207-e209.
- e32. Valálík I, van der Knaap MS, Scheper GC, Jobbágy A, Liptai Z, Csókay A. Long-term tremor control with bilateral Vim-DBS in vanishing white matter disease. *Parkinsonism Relat Disord* 2012;18:1048-1050.
- e33. Hommel S, Lücke T, Schmidt-Choudhury A. Nutritional Management in Children and Adolescents with Severe Neurological Impairment-Who Cares? A Web-Based Survey Among Pediatric Specialists in Germany. *Neuropediatrics* 2023;54:371-380.
- e34. Kaczorowska M, Kuczynski D, Jurkiewicz E, Scheper GC, van der Knaap MS, Jozwiak S. Acute fright induces onset of symptoms in vanishing white matter disease-case report. *Eur J Paediatr Neurol* 2006;10:192-193.
- e35. Vermeulen G, Seidl R, Mercimek-Mahmutoglu S, Rotteveel JJ, Scheper GC, van der Knaap MS. Fright is a provoking factor in vanishing white matter disease. *Ann Neurol* 2005;57:560-563.
- e36. Sijens PE, Boon M, Meiners LC, Brouwer OF, Oudkerk M. 1H chemical shift imaging, MRI, and diffusion-weighted imaging in vanishing white matter disease. *Eur Radiol* 2005;15:2377-2379.
- e37. Jurkiewicz E, Mierzewska H, Bekiesińska-Figatowska M, et al. MRI of a family with leukoencephalopathy with vanishing white matter. *Pediatr Radiol* 2005;35:1027-1030.
- e38. Mathis S, Scheper GC, Baumann N, et al. The ovarioleukodystrophy. *Clin Neurol Neurosurg* 2008;110:1035-1037.
- e39. Bugiani M, Postma N, Polder E, et al. Hyaluronan accumulation and arrested oligodendrocyte progenitor maturation in vanishing white matter disease. *Brain* 2013;136:209-222.
- e40. Fogli A, Boespflug-Tanguy O. The large spectrum of eIF2B-related diseases. *Biochem Soc Trans* 2006;34:22-29.
- e41. Wei C, Qin Q, Chen F, et al. Adult-onset vanishing white matter disease with the EIF2B2 gene mutation presenting as menometrorrhagia. *BMC Neurol* 2019;19:203.
- e42. Fogli A, Rodriguez D, Eymard-Pierre E, et al. Ovarian failure related to eukaryotic initiation factor 2B mutations. *Am J Hum Genet* 2003;72:1544-1550.
- e43. Ibitoye RT, Renowden SA, Faulkner HJ, Scolding NJ, Rice CM. Ovarioleukodystrophy due to EIF2B5 mutations. *Pract Neurol* 2016;16:496-499.
- e44. Robinson M, Rossignol E, Brais B, Rouleau G, Arbour JF, Bernard G. Vanishing white matter disease in French-Canadian patients from Quebec. *Pediatr Neurol* 2014;51:225-232.
- e45. Peter L, Niel F, Catenoix H, et al. Acute neurological deterioration in ovarioleukodystrophy related to EIF2B mutations: pregnancy with oocyte donation is a potentially precipitating factor. *Eur J Neurol* 2008;15:94-97.
- e46. La Piana R, Vanderver A, van der Knaap M, et al. Adult-onset vanishing white matter disease due to a novel EIF2B3 mutation. *Arch Neurol* 2012;69:765-768.
- e47. Roosendaal SD, van de Brug T, Alves C, et al. Imaging Patterns Characterizing Mitochondrial Leukodystrophies. *AJNR Am J Neuroradiol* 2021;42:1334-1340.

- e48. van der Knaap M, Bugiani M, Boor I, et al. The online metabolic and molecular bases of inherited disease (OMMBID). 2010.
- e49. Pilia RK, Anjani G, Saini AG, Jain R, Suri D, Rawat A. X-Linked Thrombocytopenia and Vanishing White Matter Disease in a Child: Double Tragedy. *J Clin Immunol* 2020;40:1176-1180.
- e50. Ohlenbusch A, Henneke M, Brockmann K, et al. Identification of ten novel mutations in patients with eIF2B-related disorders. *Hum Mutat* 2005;25:411.
- e51. Maletkovic J, Schiffmann R, Gorospe JR, et al. Genetic and clinical heterogeneity in eIF2B-related disorder. *J Child Neurol* 2008;23:205-215.
- e52. Parayil Sankaran B, Nagappa M, Chiplunkar S, et al. Leukodystrophies and Genetic Leukoencephalopathies in Children Specified by Exome Sequencing in an Expanded Gene Panel. *J Child Neurol* 2020;35:433-441.
- e53. Matsukawa T, Wang X, Liu R, et al. Adult-onset leukoencephalopathies with vanishing white matter with novel missense mutations in EIF2B2, EIF2B3, and EIF2B5. *Neurogenetics* 2011;12:259-261.
- e54. Kunii M, Doi H, Ishii Y, et al. Genetic analysis of adult leukoencephalopathy patients using a custom-designed gene panel. *Clin Genet* 2018;94:232-238.
- e55. Lee JS, Lee S, Choi M, et al. eIF2B-related multisystem disorder in two sisters with atypical presentations. *Eur J Paediatr Neurol* 2017;21:404-409.
- e56. Unal O, Ozgen B, Orhan D, et al. Vanishing White Matter With Hepatomegaly and Hypertriglyceridemia Attacks. *J Child Neurol* 2013;28:1509-1512.
- e57. Deng J, Zhou L, Zhang J, et al. Correlation Between Genotype and Age of Onset in Leukoencephalopathy With Vanishing White Matter. *Front Genet* 2021;12:729777.
- e58. Horzinski L, Huyghe A, Cardoso MC, et al. Eukaryotic initiation factor 2B (eIF2B) GEF activity as a diagnostic tool for EIF2B-related disorders. *PLoS One* 2009;4:e8318.
- e59. Benzoni C, Moscatelli M, Farina L, et al. Adult-onset leukodystrophy with vanishing white matter: a case series of 19 patients. *J Neurol* 2023;270:4219-4234.
- e60. Lee YR, Kim SH, Ben-Mahmoud A, et al. Eif2b3 mutants recapitulate phenotypes of vanishing white matter disease and validate novel disease alleles in zebrafish. *Hum Mol Genet* 2021;30:331-342.
- e61. Song H, Haeri S, Vogel H, van der Knaap M, Van Haren K. Postmortem Whole Exome Sequencing Identifies Novel EIF2B3 Mutation With Prenatal Phenotype in 2 Siblings. *J Child Neurol* 2017;32:867-870.
- e62. Dong L, Shang L, Liu C, et al. Genotypic and phenotypic heterogeneity among Chinese pediatric genetic white matter disorders. *Ital J Pediatr* 2023;49:155.
- e63. Schiffmann R, Moller JR, Trapp BD, et al. Childhood ataxia with diffuse central nervous system hypomyelination. *Ann Neurol* 1994;35:331-340.
- e64. Carra-Dalliere C, Horzinski L, Ayrignac X, et al. [Natural history of adult-onset eIF2B-related disorders: a multicentric survey of 24 cases]. *Rev Neurol (Paris)* 2011;167:802-811.
- e65. Wongkittichote P, Mar SS, McKinstry RC, Nguyen H. Case Report: A Novel EIF2B3 Pathogenic Variant in Central Nervous System Hypomyelination/Vanishing White Matter. *Front Genet* 2022;13:893057.
- e66. Wu C, Wang M, Wang X, et al. The genetic and phenotypic spectra of adult genetic leukoencephalopathies in a cohort of 309 patients. *Brain* 2023;146:2364-2376.
- e67. Lynch DS, Rodrigues Brandão de Paiva A, Zhang WJ, et al. Clinical and genetic characterization of leukoencephalopathies in adults. *Brain* 2017;140:1204-1211.
- e68. Hettiarachchi D, Neththikumara N, Pathirana B, Padeniya A, Dissanayake VHW. A Novel Mutation in the EIF2B4 Gene Associated with Leukoencephalopathy with Vanishing White Matter. *Case Rep Pediatr* 2018;2018:2731039.
- e69. Kanbayashi T, Saito F, Matsukawa T, et al. Adult-onset vanishing white matter disease with novel missense mutations in a subunit of translational regulator, EIF2B4. *Clin Genet* 2015;88:401-403.

- e70. Bursle C, Yiu EM, Yeung A, et al. Hyperinsulinaemic hypoglycaemia: A rare association of vanishing white matter disease. *JIMD Rep* 2020;51:11-16.
- e71. Buggle F, Ciric E, Boujan T, Ohlenbusch A, Gärtner J, Grau AJ. [Vanishing white matter disease in adulthood]. *Nervenarzt* 2019;90:840-842.
- e72. Wang X, He F, Yin F, et al. The use of targeted genomic capture and massively parallel sequencing in diagnosis of Chinese Leukoencephalopathies. *Sci Rep* 2016;6:35936.
- e73. Su T, Yuan H, Gao W, Li H, Yuan M. Adult Vanishing White Matter Disease with a Novel EIF2B4 Mutation. *J Coll Physicians Surg Pak* 2022;32:Ss181-ss183.
- e74. Sharma S, Arya R, Raju KN, et al. Vanishing white matter disease associated with ptosis and myoclonic seizures. *J Child Neurol* 2011;26:366-368.
- e75. Ohtake H, Shimohata T, Terajima K, et al. Adult-onset leukoencephalopathy with vanishing white matter with a missense mutation in EIF2B5. *Neurology* 2004;62:1601-1603.
- e76. Fogli A, Dionisi-Vici C, Deodato F, Bartuli A, Boespflug-Tanguy O, Bertini E. A severe variant of childhood ataxia with central hypomyelination/vanishing white matter leukoencephalopathy related to EIF2B5 mutation. *Neurology* 2002;59:1966-1968.
- e77. Rodríguez-Palmero A, Schlüter A, Verdura E, et al. A novel hypomorphic splice variant in EIF2B5 gene is associated with mild ovarioleukodystrophy. *Ann Clin Transl Neurol* 2020;7:1574-1579.
- e78. Horzinski L, Gonthier C, Rodriguez D, Scherer C, Boespflug-Tanguy O, Fogli A. Exon deletion in the non-catalytic domain of eIF2Bepsilon due to a splice site mutation leads to infantile forms of CACH/VWM with severe decrease of eIF2B GEF activity. *Ann Hum Genet* 2008;72:410-415.
- e79. Federico A, Scali O, Stromillo ML, et al. Peripheral neuropathy in vanishing white matter disease with a novel EIF2B5 mutation. *Neurology* 2006;67:353-355.
- e80. Fogli A, Wong K, Eymard-Pierre E, et al. Cree leukoencephalopathy and CACH/VWM disease are allelic at the EIF2B5 locus. *Ann Neurol* 2002;52:506-510.
- e81. Kong F, Zheng H, Liu X, Lin S, Wang J, Guo Z. Association Between Late-Onset Leukoencephalopathy With Vanishing White Matter and Compound Heterozygous EIF2B5 Gene Mutations: A Case Report and Review of the Literature. *Front Neurol* 2022;13:813032.
- e82. Trimouille A, Marguet F, Sauvestre F, et al. Foetal onset of EIF2B related disorder in two siblings: cerebellar hypoplasia with absent Bergmann glia and severe hypomyelination. *Acta Neuropathol Commun* 2020;8:48.
- e83. Takano K, Tsuyusaki Y, Sato M, et al. A Japanese girl with an early-infantile onset vanishing white matter disease resembling Cree leukoencephalopathy. *Brain Dev* 2015;37:638-642.
- e84. Bektaş G, Yeşil G, Özkan MU, Yıldız EP, Uzunhan TA, Çalışkan M. Vanishing white matter disease with a novel EIF2B5 mutation: A 10-year follow-up. *Clin Neurol Neurosurg* 2018;171:190-193.
- e85. Pena LDM, Jiang YH, Schoch K, et al. Looking beyond the exome: a phenotype-first approach to molecular diagnostic resolution in rare and undiagnosed diseases. *Genet Med* 2018;20:464-469.
- e86. Wilson CJ, Pronk JC, Van der Knaap MS. Vanishing white matter disease in a child presenting with ataxia. *J Paediatr Child Health* 2005;41:65-67.
- e87. Liu H, Wei X, Sha Y, et al. Whole-exome sequencing in patients with premature ovarian insufficiency: early detection and early intervention. *J Ovarian Res* 2020;13:114.
- e88. Alfadhel M, Almuqbil M, Al Mutairi F, et al. The Leukodystrophy Spectrum in Saudi Arabia: Epidemiological, Clinical, Radiological, and Genetic Data. *Front Pediatr* 2021;9:633385.
- e89. Alsalem A, Shaheen R, Alkuraya FS. Vanishing white matter disease caused by EIF2B2 mutation with the presentation of an adrenoleukodystrophy phenotype. *Gene* 2012;496:141-143.
- e90. Xie JJ, Ni W, Wei Q, et al. New clinical characteristics and novel pathogenic variants of patients with hereditary leukodystrophies. *CNS Neurosci Ther* 2020;26:567-575.
- e91. Ngo KJ, Rexach JE, Lee H, et al. A diagnostic ceiling for exome sequencing in cerebellar ataxia and related neurological disorders. *Hum Mutat* 2020;41:487-501.
- e92. Kami A, Langari A, Gharib MH, Ghelichi-Ghojogh M, Hosseini PS, Hosseini SA. Leukoencephalopathy with vanishing white matter disease: a case report study. *Ann Med Surg (Lond)* 2023;85:4087-4091.

- e93. Gowda VK, Srinivasan VM, Bhat M, Benakappa A. Case of Childhood Ataxia with Central Nervous System Hypomyelination with a Novel Mutation in EIF2B3 gene. *J Pediatr Neurosci* 2017;12:196-198.
- e94. Prange H, Weber T. „Vanishing white matter disease“. *Der Nervenarzt* 2011;82:1330-1334.
- e95. Richards S, Aziz N, Bale S, et al. Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology. *Genet Med* 2015;17:405-424.
- e96. Zhang Y, Li D, Li H, Hou D, Hou J. Taurine Pretreatment Prevents Isoflurane-Induced Cognitive Impairment by Inhibiting ER Stress-Mediated Activation of Apoptosis Pathways in the Hippocampus in Aged Rats. *Neurochem Res* 2016;41:2517-2525.
- e97. Ge HW, Hu WW, Ma LL, Kong FJ. Endoplasmic reticulum stress pathway mediates isoflurane-induced neuroapoptosis and cognitive impairments in aged rats. *Physiol Behav* 2015;151:16-23.
- e98. Palmer LK, Shoemaker JL, Baptiste BA, Wolfe D, Keil RL. Inhibition of translation initiation by volatile anesthetics involves nutrient-sensitive GCN-independent and -dependent processes in yeast. *Mol Biol Cell* 2005;16:3727-3739.
- e99. Wang Y, Wu D, Li D, Zhou X, Fan D, Pan J. The role of PERK-eIF2 α -ATF4-CHOP pathway in sevoflurane induced neuroapoptosis and cognitive dysfunction in aged mice. *Cell Signal* 2023;110:110841.
- e100. Liu B, Xia J, Chen Y, Zhang J. Sevoflurane-Induced Endoplasmic Reticulum Stress Contributes to Neuroapoptosis and BACE-1 Expression in the Developing Brain: The Role of eIF2 α . *Neurotox Res* 2017;31:218-229.
- e101. Palmer LK, Rannels SL, Kimball SR, Jefferson LS, Keil RL. Inhibition of mammalian translation initiation by volatile anesthetics. *Am J Physiol Endocrinol Metab* 2006;290:E1267-1275.
- e102. Li K, Han X. Endoplasmic reticulum stress is involved in the lidocaine-induced apoptosis in SH-SY5Y neuroblastoma cells. *J Mol Neurosci* 2015;56:122-130.
- e103. Bezu L, Wu Chuang A, Sauvat A, et al. Local anesthetics elicit immune-dependent anticancer effects. *J Immunother Cancer* 2022;10.
- e104. Oudejans E, Witkamp D, Schonewille P, et al. Effect of Propofol and Sevoflurane on Vanishing White Matter Models. *Pediatr Neurol* 2025;167:66-76.
- e105. Yu X, Tian AL, Wang P, et al. Macrolide antibiotics activate the integrated stress response and promote tumor proliferation. *Cell Stress* 2023;7:20-33.
- e106. Brüning A, Brem GJ, Vogel M, Mylonas I. Tetracyclines cause cell stress-dependent ATF4 activation and mTOR inhibition. *Exp Cell Res* 2014;320:281-289.
- e107. Mottis A, Li TY, El Alam G, et al. Tetracycline-induced mitohormesis mediates disease tolerance against influenza. *J Clin Invest* 2022;132.
- e108. Liu X, Chen Y, Wang H, et al. Microglia-derived IL-1 β promoted neuronal apoptosis through ER stress-mediated signaling pathway PERK/eIF2 α /ATF4/CHOP upon arsenic exposure. *J Hazard Mater* 2021;417:125997.
- e109. Ma J, Yang YR, Chen W, et al. Fluoxetine synergizes with temozolomide to induce the CHOP-dependent endoplasmic reticulum stress-related apoptosis pathway in glioma cells. *Oncol Rep* 2016;36:676-684.
- e110. Liu K, Qu Y, Li B, et al. GRP94 in cerebrospinal fluid may contribute to a potential biomarker of depression: Based on proteomics. *J Psychiatr Res* 2024;169:328-340.
- e111. Emam AM, Saad MA, Ahmed NA, Zaki HF. Vortioxetine mitigates neuronal damage by restricting PERK/eIF2 α /ATF4/CHOP signaling pathway in rats subjected to focal cerebral ischemia-reperfusion. *Life Sci* 2021;283:119865.
- e112. Halliday M, Radford H, Zents KAM, et al. Repurposed drugs targeting eIF2 α ;P-mediated translational repression prevent neurodegeneration in mice. *Brain* 2017;140:1768-1783.
- e113. Fredriksson L, Wink S, Herpers B, et al. Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNF α -mediated hepatotoxicity. *Toxicol Sci* 2014;140:144-159.

- e114. Palsamy P, Bidasee KR, Shinohara T. Valproic acid suppresses Nrf2/Keap1 dependent antioxidant protection through induction of endoplasmic reticulum stress and Keap1 promoter DNA demethylation in human lens epithelial cells. *Exp Eye Res* 2014;121:26-34.
- e115. Huang S, Zhu M, Wu W, et al. Valproate pretreatment protects pancreatic β -cells from palmitate-induced ER stress and apoptosis by inhibiting glycogen synthase kinase-3 β . *J Biomed Sci* 2014;21:38.
- e116. Sun XY, Qin HJ, Zhang Z, et al. Valproate attenuates diabetic nephropathy through inhibition of endoplasmic reticulum stress-induced apoptosis. *Mol Med Rep* 2016;13:661-668.
- e117. Fu J, Peng L, Wang W, et al. Sodium Valproate Reduces Neuronal Apoptosis in Acute Pentylentetrazole-Induced Seizures via Inhibiting ER Stress. *Neurochem Res* 2019;44:2517-2526.
- e118. Wu X, Wang A, Xu L, et al. Valsartan Attenuated Homocysteine-Induced Impaired Autophagy and ER Stress in Human Umbilical Vein Endothelial Cells. *Cardiovasc Ther* 2023;2023:8817431.
- e119. Kim BS, Park IH, Lee AH, Kim HJ, Lim YH, Shin JH. Sacubitril/valsartan reduces endoplasmic reticulum stress in a rat model of doxorubicin-induced cardiotoxicity. *Arch Toxicol* 2022;96:1065-1074.
- e120. He M, Huang XF, Gao G, et al. Olanzapine-induced endoplasmic reticulum stress and inflammation in the hypothalamus were inhibited by an ER stress inhibitor 4-phenylbutyrate. *Psychoneuroendocrinology* 2019;104:286-299.
- e121. Laressergues E, Bert E, Duriez P, et al. Does endoplasmic reticulum stress participate in APD-induced hepatic metabolic dysregulation? *Neuropharmacology* 2012;62:784-796.
- e122. Tran TH, Kao M, Liu HS, Hong YR, Su Y, Huang CF. Repurposing thioridazine for inducing immunogenic cell death in colorectal cancer via eIF2 α /ATF4/CHOP and secretory autophagy pathways. *Cell Commun Signal* 2023;21:184.
- e123. Carraro V, Combaret L, Coudy-Gandilhon C, et al. Activation of the eIF2 α -ATF4 Pathway by Chronic Paracetamol Treatment Is Prevented by Dietary Supplementation with Cysteine. *Int J Mol Sci* 2022;23.
- e124. Liu H, Xiong C, Liu J, et al. Aspirin exerts anti-tumor effect through inhibiting Blimp1 and activating ATF4/CHOP pathway in multiple myeloma. *Biomed Pharmacother* 2020;125:110005.
- e125. Liu HC, Xiong C, Geng J, et al. [Expression of Blimp1、ATF4 and CHOP in Multiple Myeloma Cells and Effect of Aspirin on Their Expression]. *Zhongguo Shi Yan Xue Ye Xue Za Zhi* 2020;28:165-170.
- e126. Alhusaini S, McGee K, Schisano B, et al. Lipopolysaccharide, high glucose and saturated fatty acids induce endoplasmic reticulum stress in cultured primary human adipocytes: Salicylate alleviates this stress. *Biochem Biophys Res Commun* 2010;397:472-478.
- e127. Silva AM, Wang D, Komar AA, Castilho BA, Williams BR. Salicylates trigger protein synthesis inhibition in a protein kinase R-like endoplasmic reticulum kinase-dependent manner. *J Biol Chem* 2007;282:10164-10171.
- e128. Gentz SH, Bertollo CM, Souza-Fagundes EM, da Silva AM. Implication of eIF2 α kinase GCN2 in induction of apoptosis and endoplasmic reticulum stress-responsive genes by sodium salicylate. *J Pharm Pharmacol* 2013;65:430-440.
- e129. Leung YF, Tam PO, Lee WS, et al. The dual role of dexamethasone on anti-inflammation and outflow resistance demonstrated in cultured human trabecular meshwork cells. *Mol Vis* 2003;9:425-439.
- e130. Ikegaki N, Hicks SL, Regan PL, et al. S(+)-ibuprofen destabilizes MYC/MYCN and AKT, increases p53 expression, and induces unfolded protein response and favorable phenotype in neuroblastoma cell lines. *Int J Oncol* 2014;44:35-43.
- e131. Chaudhary SC, Waseem M, Rana M, et al. Naproxen Inhibits UVB-induced Basal Cell and Squamous Cell Carcinoma Development in Ptch1(+/-) /SKH-1 Hairless Mice. *Photochem Photobiol* 2017;93:1016-1024.
- e132. Tsutsumi S, Gotoh T, Tomisato W, et al. Endoplasmic reticulum stress response is involved in nonsteroidal anti-inflammatory drug-induced apoptosis. *Cell Death Differ* 2004;11:1009-1016.



https://ec.europa.eu/health/ern_en



 **Network**
Neurological Diseases
(ERN-RND)

 **Coordinator**
Universitätsklinikum
Tübingen — Deutschland

www.ern-rnd.eu

Co-funded by the European Union



- e133. Boonyong C, Vardhanabhuti N, Jianmongkol S. Modulation of non-steroidal anti-inflammatory drug-induced, ER stress-mediated apoptosis in Caco-2 cells by different polyphenolic antioxidants: a mechanistic study. *J Pharm Pharmacol* 2020;72:1574-1584.
- e134. Tsutsumi S, Namba T, Tanaka KI, et al. Celecoxib upregulates endoplasmic reticulum chaperones that inhibit celecoxib-induced apoptosis in human gastric cells. *Oncogene* 2006;25:1018-1029.
- e135. Namba T, Hoshino T, Tanaka K, et al. Up-regulation of 150-kDa oxygen-regulated protein by celecoxib in human gastric carcinoma cells. *Mol Pharmacol* 2007;71:860-870.
- e136. Namba T, Ishihara T, Tanaka K, Hoshino T, Mizushima T. Transcriptional activation of ATF6 by endoplasmic reticulum stressors. *Biochem Biophys Res Commun* 2007;355:543-548.
- e137. Cusimano A, Azzolina A, Iovanna JL, et al. Novel combination of celecoxib and proteasome inhibitor MG132 provides synergistic antiproliferative and proapoptotic effects in human liver tumor cells. *Cell Cycle* 2010;9:1399-1410.
- e138. Zhang X, Lee SH, Min KW, et al. The involvement of endoplasmic reticulum stress in the suppression of colorectal tumorigenesis by tolfenamic acid. *Cancer Prev Res (Phila)* 2013;6:1337-1347.
- e139. Avcı O, Taşkıran A. Anakinra, an interleukin-1 receptor antagonist, increases the morphine analgesic effect and decreases morphine tolerance development by modulating oxidative stress and endoplasmic reticulum stress in rats. *Turk J Med Sci* 2020;50:2048-2058.
- e140. Fan R, Schrott LM, Snelling S, Ndi J, Arnold T, Korneeva NL. Chronic oxycodone induces integrated stress response in rat brain. *BMC Neurosci* 2015;16:58.
- e141. Fan R, Schrott LM, Arnold T, et al. Chronic oxycodone induces axonal degeneration in rat brain. *BMC Neurosci* 2018;19:15.
- e142. Zhou L, Yang X, Shu S, et al. Sufentanil Protects the Liver from Ischemia/Reperfusion-Induced Inflammation and Apoptosis by Inhibiting ATF4-Induced TP53BP2 Expression. *Inflammation* 2021;44:1160-1174.
- e143. Zhao L, Zhai M, Yang X, et al. Dexmedetomidine attenuates neuronal injury after spinal cord ischaemia-reperfusion injury by targeting the CNPY2-endoplasmic reticulum stress signalling. *J Cell Mol Med* 2019;23:8173-8183.
- e144. Huang M, Wang J, Zhai M, et al. Sigma-1 receptor regulates the endoplasmic reticulum stress pathway in the protective mechanism of dexmedetomidine against hyperoxia-induced lung injury. *Biochim Biophys Acta Mol Basis Dis* 2024;1870:166885.
- e145. Chen Y, Cao S, Chen H, Yin C, Xu X, Yang Z. Dexmedetomidine Preconditioning Reduces Myocardial Ischemia-Reperfusion Injury in Rats by Inhibiting the PERK Pathway. *Arq Bras Cardiol* 2021;117:1134-1144.
- e146. So EC, Chen YC, Wang SC, et al. Midazolam regulated caspase pathway, endoplasmic reticulum stress, autophagy, and cell cycle to induce apoptosis in MA-10 mouse Leydig tumor cells. *Onco Targets Ther* 2016;9:2519-2533.
- e147. Kang FC, Wang SC, Chang MM, et al. Midazolam activates caspase, MAPKs and endoplasmic reticulum stress pathways, and inhibits cell cycle and Akt pathway, to induce apoptosis in TM3 mouse Leydig progenitor cells. *Onco Targets Ther* 2018;11:1475-1490.
- e148. Fu P, Wu Q, Hu J, Li T, Gao F. Baclofen Protects Primary Rat Retinal Ganglion Cells from Chemical Hypoxia-Induced Apoptosis Through the Akt and PERK Pathways. *Front Cell Neurosci* 2016;10:255.